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Abstract 
Mitochondrial biogenesis is a process by which the cell increases its mitochondrial content, 
involving nuclear-derived and mitochondrial -derived protein synthesis and assembly. Previous 
literature has identified retinoic acid as a viable agonist of mitochondrial biogenesis in liver and 
fat tissue, but whether retinoic acid has this effect on muscle is currently unknown. We decided 
to investigate the effects of retinoic acid on muscle mitochondrial biogenesis by testing it on 
muscle cells. We also combined RA isomers with known activators of mitochondrial biogenesis, 
including the drug Nicotinamide Riboside (NR), as well as a model of contracting muscle cells, 
in order to observe whether there are any interactions. Our results indicate that RA isomer 
treatment can induce mitochondrial biogenesis, and when combined with chronic contractile 
activity, has the potential to be additive or synergistic. This suggests that RA may be a useful 
supplement to accompany exercise training.  
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1.0 Mitochondria  
The presence of energy-producing organelles known as mitochondria was known as early as 
1890 due to the histology research of Richard Altmann. Mitochondria have been postulated to 
originate in eukaryotic cells as engulfed endosymbiotic descendants of α-proteobacteria (4, 5, 
41). Mitochondria produce energy in the form of adenosine triphosphate (ATP) and play a part in 
maintaining metabolic homeostasis in the cell. These dynamic organelles are able to grow, divide 
and fuse into granular or reticular structures (65, 68, 87, 156) and localize to areas of the tissue 
that require more energy.  The distribution and organization of mitochondria changes across 
different tissue types, with cardiac muscle having a high mitochondrial content, while skeletal 
muscle has a relatively low content per gram of tissue (46, 52, 65)The mitochondrion is divided 
into four compartments: 1) the outer mitochondrial membrane (OMM), 2) the intermembrane 
space (IMS), 3) the inner mitochondrial membrane (IMM), and 4) the matrix. 
Mitochondria are unique organelles that contain their own set of genomes (4, 51, 65, 72, 
107, 120, 124). The genome encodes 13 of the ≈1200 proteins responsible for oxidative 
phosphorylation (OXPHOS (5) which is the process responsible for generating most of the ATP 
in the cell. The remaining proteins that are found in the mitochondria are nuclear-encoded 
precursors, which are synthesized outside of the mitochondria in the cytosol (72, 134). These 
precursor proteins are imported by chaperones into mitochondria through the protein import 
machinery(12, 53, 58, 67, 104, 139). The precursors typically enter through the Tom (translocase 
of the outer mitochondrial membrane) and Tim (translocase of the inner mitochondrial 
membrane) complexes (11, 34), and are incorporated into the electron transport chain (ETC).  
The ETC is responsible for OXPHOS and energy generation. The OMM is implicated in 
apoptosis, due to an increase in membrane permeability, leading to a disruption in mitochondrial 
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function, and a release in pro-apoptotic proteins(30, 55, 116). The IMS serves as  the region 
where protons from the matrix by the ETC are expelled to in order to create a electrochemical 
gradient that allows ATP synthase to produce ATP (42, 69, 70). The IMM is characterized by 
membrane folds that maximize surface area, and are termed cristae. The IMM separates the IMS 
and the matrix, and contains the ETC and  its components (58). The matrix, the final component, 
contains about 2/3 of the total protein in a mitochondrion, and contains hundreds of enzymes, 
special mitochondrial ribosomes, tRNAs, and multiple copies of the mitochondrial DNA genome 
(34). The major functions include the oxidation of pyruvate and fatty acids, and the citric acid 
cycle.  
1.1 Mitochondrial Structure and Function in Muscle 
Skeletal muscle has a low basal level of mitochondrial content (46). However, muscle tissue is 
incredibly plastic in terms of mitochondrial turnover. In skeletal muscle, there are two distinct 
populations of mitochondria; one positioned close to the sarcolemma (SS mitochondria), other 
embedded among the myofibrils (IMF mitochondria) (1, 53) .With physiological stimuli such as 
exercise, muscle tissue expands the reticular mitochondrial network (32, 65, 74, 89) and contains 
more mitochondria to meet the new metabolic demands. The concentration of mitochondria and 
formation of this reticular network is governed by mitochondrial turnover and mitochondrial 
fission and fusion.  Mitochondria are also involved in cellular handling of Ca
2+
, via their uptake 
and release ability through their mitochondrial permeability transition pore, and can also play a 
role in apoptosis and programmed cell death (39, 97).  
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1.2 Electron Transport Chain  
The ETC is a complex of proteins responsible for the production of ATP from the products of 
lipid oxidation, citric acid cycle products and amino acid oxidation. The ETC contains a series 
of redox reactions, in which electrons are transferred from donor molecule to an acceptor 
molecule. Five complexes are found in the ETC (Complexes I-V), which functions to carry 
electrons to the terminal electron acceptor, oxygen. The reduced equivalents of NAD and FAD 
deliver the electrons to the complexes, NADH to complex 1 and FADH to complex 2.  The 
electron flow, combined with the translocation of protons from the matrix to the intermembrane 
space (via complexes I, III and IV) generate an electrochemical proton gradient or membrane 
potential (ΔΨm) across the inner mitochondrial membrane. This gradient is utilized by ATP 
synthase to generate ATP from ADP and inorganic phosphate (Pi). Over the course of this 
process, some of the electrons can leak out of this pathway, and reduce O2 to superoxide radical 
(O2
•−
), leading to the production of reactive oxygen species (ROS). ROS can be detoxified by the 
action of antioxidant enzymes such as superoxide dismutase, catalase, and glutathione 
peroxidase (5, 85, 134). In cases where the ROS production outpaces the ability of antioxidants 
to scavenge, a buildup of ROS can occur and cause mitochondrial dysfunction and oxidative 
stress, which is highly damaging to cellular components. ROS buildup has been linked to 
multiple pathologies including neurodegenerative diseases, diabetes, cancer and premature aging 
(2, 16, 20, 30, 68, 143).  Higher energy-demanding tissues like muscle are more susceptible to 
such oxidative stress.   
2.0 Mitochondrial Turnover 
Mitochondrial Turnover is a process by which optimal functioning of the mitochondrial pool is 
achieved, and energy homeostasis is maintained. The mitochondrial network consists of many 
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mitochondria, which can be added or removed from the network via fusion or fission (7, 23, 39, 
65, 147). The turnover of these organelles is comprised of two processes: the creation of new and 
healthy mitochondria via biogenesis, and the removal of old and dysfunctional mitochondria via 
autophagy (mitophagy). This balance can be tilted toward either biogenesis or autophagy, 
depending on the stimulus. Exercise and pharmacological treatment are able to activate signaling 
events leading to elevations in the activity of downstream proteins like transcription factors 
responsible for impacting the expression of nuclear genes encoding mitochondrial proteins 
(NUGEMPS) (33, 65, 72, 87, 124, 134). This leads to the mRNA expression of NUGEMPS, 
which are translated into precursor proteins attached to a chaperone and transported to the site of 
mitochondrial protein import machinery (58, 111, 139). Precursor proteins are then guided to the 
appropriate compartments, such as the matrix, or inner or outer mitochondrial membrane, and 
integrated into the mitochondrion. Conversely, an elevation in the mitophagy to mitochondrial 
biogenesis ratio will lead to the activation of mitochondrial degradation via the autophagosome-
lysosome pathway (ALP), and this mechanism is regulated in a similar coordinated signaling 
mechanism. Potential triggers of mitophagy include hypoxia (74, 90, 123), ROS (2, 30, 52, 143) 
or a decrease in mitochondrial membrane potential (30, 55). Enough damage done to the 
mitochondrion will result in the dysfunctional portion of the mitochondrial reticulum being 
sectioned off by fission, and specifically targeted for degradation (21, 29, 55). Dysfunction in the 
proper maintenance of mitochondrial turnover has the potential to lead to the development of 
cardiovascular diseases (36, 83, 135), cancer (5, 20, 143), metabolic impairment (5, 19, 36, 57, 
96), and earlier aging.   
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2.1 Mitochondrial Biogenesis in Muscle 
As previously mentioned, skeletal muscle is a very plastic tissue that can adapt to the metabolic 
demands placed upon it. These metabolic demands can come from either muscle regeneration, 
the development of the myoblast into a myotube, or, through exercise-stimulated mitochondrial 
biogenesis (37, 46, 61, 63, 66, 70, 74, 79, 85, 87 92, 107, 116, 126, 151). As a muscle develops 
from the immature myoblasts into myotubes, the cells undergo a switch in metabolic profile from 
one that is glycolytic to a primarily oxidative phosphorylation profile with complex 
mitochondrial networks built to support the metabolic demands of the new muscle fibre. Along 
with the increase in mitochondria, there is a reorganization of the mitochondrial networks to 
areas of greatest metabolic demand (37, 49, 145, 147, 155).  
When the metabolic demands placed on the tissue exceed the capacity of the existing 
mitochondrial networks, there is a cascade of signaling events that activates transcription factors 
such as cAMP response element-binding protein (CREB). The CREB transcription factors 
function to modify and activate other transcription factors, which facilitate an increase in 
mitochondrial content in a process termed mitochondrial biogenesis. The peroxisome 
proliferator- activated receptor gamma coactivator alpha (PGC-1α) has been identified as the 
master regulator and transcriptional coactivator that facilitates the activation of these 
transcription factors in muscle and other tissues (17, 34, 56, 156, 62, 64, 66, 71, 74, 81, 86,93, 
95, 98, 112,127, 134–136,140,153). Additional research on PGC-1α had revealed that it interacts 
with the nuclear respiration factors (NRFs) 1 and 2 (25, 42, 61, 72, 82, 109, 119, 120, 124, 133) 
in order to facilitate mitochondrial biogenesis by promoting the transcription of NUGEMPS. The 
result is an increase in NUGEMP mRNAs, which includes components of the mitochondrial 
ETC, as well as mitochondrial transcription factor A (Tfam), a protein that serves to interact with 
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the mtDNA to facilitate the transcription and mRNA synthesis of the 13 mitochondrially-derived 
proteins (27, 51, 67, 82, 87, 106, 107, 120, 147). The increase in mitochondrial content allows 
for improved metabolic function and exercise capacity. The following chapter will examine the 
role of exercise in mitochondrial biogenesis in muscle.  
2.1.1 Mitochondrial Biogenesis and Exercise Training 
The pioneering work of Dr. John Holloszy in the 1960’s on rats undergoing strenuous bouts of 
treadmill running revealed that several ETC components increased approximately 2-fold in 
hindlimb muscles in response to the training, while the total protein content of the mitochondrial 
fraction increased approximately 60% (62). This study served as a strong foundational link 
between exercise and mitochondrial biogenesis. Exercise training, for the most part,  can be 
broken down into endurance training and resistance training. Endurance training has been 
implicated with mitochondrial biogenesis by increasing the lactate threshold (32, 40), OXPHOS 
components of the ETC (66, 69) and oxygen utilizing capacity (65, 68, 72, 74, 94).  Endurance 
training can vary by frequency, intensity, time and type (89), and consists of repetitive 
submaximal contractile activation of large muscle groups in the body. Depending on the intensity 
of the exercise regimen, between 50-100% increases in mitochondrial content in a 6 week period 
was observed, resulting in elevated endurance capacity and higher maximal oxygen 
consumption. Conversely, resistance training does not serve to expand total mitochondrial 
content; rather, it functions to optimize the quality of currently present mitochondria via 
functional improvement (38).   
Continuous contractile activity triggers four main signalling molecules: 1) a rise in 
cytosolic calcium (Ca
2+
) accumulation, sensed by Calcium/calmodulin-dependent protein kinases 
(CaMKs) (63, 118, 153); 2) phosphorylation of p38 MAPK (6, 10, 85, 153), 3) phosphorylation 
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of AMP-activated protein kinase (AMPK) in response to decreases in ATP to AMP ratio (18, 
72); and 4) production of reactive oxygen species (ROS) (68, 153).  These pathways facilitate the 
activation of the master regulator of mitochondrial biogenesis, PGC-1α.   
2.2 Cell Culture Model of Mitochondrial Biogenesis 
In order to elucidate the mechanisms of mitochondrial biogenesis in muscle, cell culture models 
can be used to provide an isolated and well-controlled environment with minimal confounding 
variables.  Typically when investigating biochemical processes, in-vitro studies allow scientists 
to examine the effect of drug treatments or knockouts on a specific cell type, while in-vivo 
treatment involves the whole organism, and may lead to other confound effects leading to 
adverse reactions or offspring that are not viable past development. Cell culture offers an 
alternative avenue where drug safety/knockout effects can be tested with great specificity on one 
cell type. When examining muscle cell biogenesis in vitro, it can be separated into two sections: 
differentiation-based biogenesis and chronic contractile activity (CCA)-based biogenesis (31, 65, 
133).  
Differentiation-induced mitochondrial biogenesis occurs during the cell developmental process, 
by which quiescent muscle stem cells are activated by stimuli from their environment.  The stem 
cells are stimulated to undergo division, creating a replicate of the original stem cell and a 
myogenic progenitor cell called a myoblast (155). The myoblast undergoes differentiation in 
which several myoblasts fuse into multinucleated contractile units called myotubes (59, 146). 
The process of myogenesis requires considerable amounts of energy, leading to the activation of 
regulatory pathways and mitochondrial biogenesis in order to support the elevated metabolic 
demands (138).  The knockout of mtDNA in myoblasts impaired differentiation, while 
proliferation remained unaffected (60). Additionally, blocking mitochondrial protein synthesis 
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with the inhibitor chloramphenicol also stunted differentiation (56). Taking these two 
observations together, it appears that differentiation is a powerful stimulus for mitochondrial 
biogenesis. The importance of mitochondrial networks and biogenesis is also supplemented by 
the discovery of the remodeling of previously formed mitochondrial networks in myoblasts 
preceeds the formation of new mitochondrial networks that are optimized to support myotubes 
(7, 23, 99). The myoblasts are much more reliant on glycolysis and their mitochondria are not as 
metabolically potent as those of a myotube (125).  
 Chronic Contractile Activity (CCA) is the second model for mitochondrial biogenesis, 
and it involves electrically-induced chronic contractions (31, 78). The electrical activation in 
motor neurons during in vivo training can be mimicked with electrical stimulation. In vitro 
stimulation of myotubes involves the input of parallel platinum wires attached to an external 
stimulator that sends a current through the myotubes, depolarizing them and initiating contractile 
activity. Previous studies have indicated that 3 hours of stimulation over the course of 4 days is 
sufficient to elucidate significant mitochondrial adaptations (31, 94, 133).  The muscle cells 
adapt in a manner similar to that during exercise. Cell culture offers the additional benefit of 
investigating the effect on muscle tissue alone, removing the systemic whole body effects of 
exercise.  CCA stimulates action potentials, causing calcium release and augmenting the levels 
of COX proteins, Tfam, NUGEMPS and PGC-1α, thus showing mitochondrial biogenesis (2, 69, 
133).  
2.3 Mitophagy 
Mitophagy is the process by which damaged and dysfunctional mitochondria are removed from 
the mitochondrial network and broken down into simple amino acids and lipids (23, 29, 66, 122, 
125).  Mitophagy functions as a quality control mechanism in the cell to preserve optimal 
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mitochondrial function.   The term was adapted from autophagy, where mitophagy refers to the 
specific autophagy of mitochondria. Dysfunctional mitochondria exert damaging effects on the 
cell, and to manage this risk, mitochondria display several lines of quality control mechanisms. 
Some of these mechanisms include mitochondria-specific chaperones and proteases that protect 
against misfolded proteins at the molecular level, as well as antioxidants to scavenge ROS 
produced by the mitochondria (104). However, if the damage accrued to the mitochondrion 
cannot be handled by these mechanisms, dysfunctional mitochondria will be removed from the 
network by fission proteins (7, 67) and targeted for mitophagy. Mitophagy is typically triggered 
due to loss of mitochondrial potential, leading to an impairment in the ability of the  ETC to 
produce ATP, an increase in ROS production and subsequent damage to the cell.  Once targeted, 
E3 ubiquitin ligases will bind to mitochondrial proteins on the outer membrane, and stimulate the 
activation of adaptor proteins like p62 that bind to microtubule associated protein 1 light chain 3 
(LC3) proteins. LC3 is lipidated from LC3-1 to LC3-2 by autophagy related protein 3 (Atg3) and 
this begins to form a vesicle encapsulating the mitochondrion, forming a structure called an 
autophagosome (48, 54, 55). The autophagosome is transported along microtubules to the 
lysosome, until it interacts with the lysosome associated membrane proteins-1 (LAMP-1) and 
LAMP-2, and is engulfed into the lysosome.  The lysosome uses its acid environment to break 
down the contents, with the help of proteases such as cathepsin D that function to degrade 
proteins and activate precursors of bioactive proteins in pre-lysosomal compartments.  
2.3.1 Mitophagy Pathways 
There are multiple autophagic proteins that are thought to be potential players in mitophagy (23, 
29, 66, 80, 93, 122), the most characterized of which involves PINK-1 and Parkin. Once the 
mitochondrial membrane potential is reduced, the mitochondrial serine/threonine kinase, 
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Phosphatase and tensin homolog-induced putative kinase 1 (PINK-1), begins to assimilate on the 
outer mitochondrial membrane. The binding of PINK-1 recruits Parkin, a cytosolic E3 ubiquitin 
ligase that has been linked to Parkinson’s disease (7, 23, 29, 55, 122). In healthy mitochondria 
with an optimal mitochondrial membrane potential, PINK1 is imported into the mitochondrial 
inner membrane, where it is cleaved by PARL and consequently degraded (93). The binding of 
Parkin to the mitochondrial membrane components like voltage-dependent anion channel 
(VDAC) results in the ubiquitination of mitochondrial components. PINK-1 will also 
phosphorylate the ubiquitin chain, recruiting cytosolic autophagic proteins such as the ULK and 
PI3K complex to the phagophore assembly site. The adaptor protein p62 also binds to the 
ubiquitin structure, and facilitates the binding to the LC3-2-phagosome structure around the 
mitochondrion, thereby forming the autophagosome. 
 Another pathway of mitophagy operates via BNIP-3 and NIP3-like protein X (NIX). 
BNIP3 and NIX are proteins related to the BH3-only family, which induce both cell death and 
hypoxia-mediated autophagy in cancer (26, 55, 92) and heart disease (92). The mechanism by 
which BNIP3/NIX begins is with the activation and insertion of BNIP3 and NIX and the opening 
of MPTP through an interaction with BAX or BAK, or a component of the mitochondrial 
permeability transition pore (MPTP).  This leads to a loss of mitochondrial membrane potential, 
generation of reactive oxygen species, and eventual mitophagy. This system of mitophagy has 
garnered contrasting research, with some studies suggesting that this form of autophagy is 
necrotic in nature (92), while other studies show that in cases like cardiac hypoxia, this 
autophagic pathway can be protective (92). A second model of NIX-dependent mitophagy 
assumes that NIX possesses an ability to recruit autophagy components, independent of 
triggering mitochondrial depolarization (101, 149). NIX deficiency does not generally impair 
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autophagy in erythroid cells, but instead interferes with the targeting of mitochondria to 
autophagosomes. A study consistent with these findings found that NIX functions as an adaptor 
protein that recruits components of the autophagy machinery to mitochondria (101). A third 
model of NIX-dependent mitophagy is derived from a recently proposed model of crosstalk 
between autophagy and cell death pathways, where both BNIP3 and Beclin-1 were initially 
identified as BCL2 or BCL-XL-interacting proteins. The theory is that BNIP and NIX are able to 
competitively bind Beclin-1, and in this manner attenuate BCL-2 binding and inactivate Beclin-1 
(149).  
2.4 Protein Import Machinery 
Mitochondria consist of two membranes, the outer membrane and the folded inner membrane, 
and two aqueous compartments, the intermembrane space and the matrix containing 
mitochondrial DNA (58, 139). Mitochondria play crucial roles in cellular energy production and 
in the metabolism of amino acids, iron, and lipids, as well as in apoptosis. Proteome analyses 
indicate that mitochondria contain approximately 1,500 different proteins in humans (137).  
Although mitochondria possess their own DNA, only about 1% of all mitochondrial proteins are 
encoded by the mitochondrial genome. The vast majority of mitochondrial proteins are 
synthesized as precursor proteins in the cytosol and are imported mainly by a post-translational 
mechanism. In order for these proteins to reach the inner mitochondrial membrane, they must be 
transported through the mitochondrial import machinery system. In the canonical pathway,  the  
matrix-destined proteins are typically tagged with a N-terminal that function as targeting signals, 
and are imported through the translocase complex  of the outer membrane (Tom), and the 
translocase complexes of the inner mitochondrial membrane (Tims) (58). The Tom complex is 
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responsible for proteins destined for the inner membrane space, matrix destined proteins, and the 
inner mitochondrial membrane destined proteins (11, 12, 34).  
Once the target proteins enter the Tim complexes, they will localize to either the Tim23 
or the Tim22 complex, depending on the destination. The proteins with a matrix-targeted signal 
will interact with the Tim23 complex, while those that lack this signal will interact with the 
Tim22 complex (11).  The matrix-destined proteins enter the Tim23 complex, after which the 
precursor sequence of the proteins is clipped off, and they are pulled into the matrix via the 
chaperone protein mtHSP70 (104). This protein will then be exchanged with another chaperone, 
mtHSP60, which will deliver it the transcription factor to the nucleus and allow it to exert its 
genomic effects. 
3.0 Retinoic Acid 
Retinoic acid is a derivative of vitamin A, also known as retinol. Sources of Vitamin A include 
carrots as provitamin A (which can be converted into retinol) and liver tissue as retinyl esters.  
Upon ingestion of retinol, it is transported to the liver via cytosolic retinoid binding proteins 
(CRBP’s) where it can undergo esterification to retinyl esters and eventual transport for 
utilization for vision in the retina, or transport to other cell types and consequent conversion into 
retinaldehyde. Retinaldehyde is  then broken  down by retinoic aldehyde dehydrogenase 1 
(RALDH-1) into retinoic acid isomers (20). Retinoic acids are then bound to cytosolic retinoic 
acid binding proteins (CRABPS), and shuttled to neighboring cells, where they can diffuse 
through the lipid bilayer and interact with  nuclear and mitochondrial receptors to exert their 
genomic effects. Retinoic acids control over 530 genes (9), which include genes responsible for 
metabolic and developmental processes. The utilization of retinoic acid in the organism is tightly 
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regulated, as effects vary on location, concentration and timing. The importance of these 
transporters will be further explored in chapters 3.1 and 3.2. 
 Two naturally occurring RA isomers, 9-cis retinoic acid (9-cisRA) and all-trans retinoic 
acid (ATRA), are of great interest due to their natural presence in the body, as well as due to 
their high affinity for retinoid receptors. Recent studies have investigated the effects of retinoic 
acid treatment in adipose, neurons and liver tissue (7, 96, 101, 129, 131, 144, 152, 154), and have 
shown significant elevations in mitochondrial biogenesis and oxygen consumption, which 
suggests they could affect muscle mitochondrial biogenesis. In these studies, both of the RA 
isomers facilitated an increase in PGC-1α mRNA levels, and ATP production levels, as well as 
SDHA-1, a marker of mitochondrial content (14, 43). In L6 muscle cells, retinoic acid treatment 
led to elevations in glucose transporters GLUT1 and GLUT 4 mRNA (125).   
3.1 Retinoic Acid and Nuclear Gene Expression  
Retinoic acid isomers 9cisRA and ATRA exert their genomic effects via the retinoic acid 
response elements (RARE), which involve the RAR and RXR receptors. The 9cisRA isomer is 
able to bind and activate both RAR and RXR, while ATRA only targets RAR. Each of these 
receptors can be further classified into 3 different subtypes, α, β, and γ, which have some 
overlapping functions. RAR are able to heterodimerize with other receptors such as PML (103), 
these receptors typically bind with RXR to produce RARE sites, while RXR receptors can also 
form heterodimers with members of the PPAR/thyroid/steroid/vitamin-D families of receptors 
(14, 43, 84, 108). As previously mentioned, RARE sites are prominent in many tissues and 
regulate the transcription of a wide array of genes, so the focus of this review will revolve around 
those relevant to muscle and muscle cell metabolism.  
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The effects RA exerts on the cells can depend on the presence of the two main RA 
transporters in the cell, CRABPs and fatty acid binding proteins (FABPs) (110, 121, 144). 
Tissues with higher levels of CRABPs will transport the RA to RAR/RXR RARE sites that 
promote cell cycle arrest and differentiation, while the RA bound to FABP-5 will be shuttled to 
PPAR/RXR  RARE sites, and be involved in cell proliferation and energy homeostasis (110, 
121, 144).  This direct activation of the nuclear genome leads to the transcription of a wide array 
of genes associated with mitochondrial biogenesis, some of which focus on PPAR activation 
(Figure 1). The binding to FABP-5 will result in the RA being carried to PPAR receptors.  Once 
FABP-5 delivers the RA to the receptor, RA will bind to PPAR and activate the transcription of 
proteins responsible for energy homeostasis and insulin responses (8, 17, 113, 115, 126).  A 
similar form of binding occurs with 9-cisRA and RXR/PPAR receptors. The 9cis-RA isomer can 
bind both receptors, and once it binds to PPAR, it will initiate the transcription of proteins 
responsible for energy homeostasis and insulin responses as well. The potency of 9cisRA in 
terms of activating both RA receptors could explain why in research in diabetic rats, 9cis-RA 
proved more effective in restoring mitochondrial function than ATRA.  
The indirect gene activation is accomplished via the binding of RA to RAR receptors 
found in the lipid rafts of the cell membrane, and eventual activation of kinases. Upon binding, a 
cascade of kinase activity is initiated, and these kinases include p38 MAPK or p42/44 MAPK, 
AMPK and CAMKII (9, 73, 146). The activation of kinases leads to PGC-1α transcription and 
phosphorylation, facilitating the activation the NRF/PPAR families of nuclear receptors, leading 
to transcription of mitochondrial proteins (120, 124).  In addition to phosphorylating PGC-1α, 
RA’s can also phosphorylate Mitogen and Stress-activated protein Kinase 1 (MSK-1), which will 
then phosphorylate a serine on the ligand binding domain (LBD) of RAR.  This activation leads 
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to the recruitment of cyclin H/cdk 7 complex, which acts to phosphorylate RAR and allow it to 
be re-recruited to RAREs, where it will dimerize with RXR and initiate the transcription of target 
genes. In this configuration, RXR is dimerized in a non-permissive manner, meaning that only if 
RAR is bound will the RXR be able to be targeted by a ligand.  
Overall, the signalling of retinoic acids is complex, and for the sake of simplifying 
pathways to those relevant to muscle cells and mitochondrial biogenesis, the focus of this review 
was to examine the activation of mitochondrial biogenesis via RARE and PPAR activation, or 
the indirect activation via the kinase activation pathway.  
3.2 Retinoic Acid and Mitochondrial Gene Expression  
Several mitochondral genes have been shown to be regulated by retinoic acid. These include 
NADH dehydrogenase subunit 5 (ND5; 5), cytochrome c oxidase subunit I mRNA, and 
16srRNA, ATPase 6, ATPase 6, 8, and ND1, as well as protein levels of ATPase subunit a (6 
gene) in a dose-dependent manner that peaked at 1nM (14, 43).  When examining the possible 
mechanisms by which RA could be modulating the expression of these genes, there have been 
three potential mechanisms that have been identified:  insulin-glucose mediated arch, the 
elevation of Tfam, and finally, the activation of RARE sites on the mtDNA. The optimal dose for 
mitochondrial functioning was found to vary across genotypes (43) . In a rat model mimicking 
human diabetes mellitus, is was observed that diabetic rats required more Vitamin A to attenuate 
the diabetic symptoms by restoring glucose-stimulated insulin secretion and reducing glucagon 
secretion (44) .   
 The second potential mechanism that has been identified came from the observation that 
increased dietary vitamin A can upregulate Tfam protein expression in adipocytes (14, 43, 44). 
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The mechanism by which this occurs is still unknown. It has been postulated that this could 
either be a direct effect on Tfam transcription, or via posttranscriptional regulation of Tfam by 
increased mtDNA levels. In addition to the activation of RARE sites in the nuclear genome, it 
has been shown that the mitochondria also possess RARE sites in their DNA, located in the 
heavy strand (43).  This area of research is somewhat controversial.  Receptors for peroxisome 
proliferators have been shown to localize to mitochondria, and retinoid receptors could 
potentially dimerize with these receptors and facilitate their activity. Recent research has shown 
the presence of CRABP I and II in mitochondria. Their function in mitochondria is currently 
under investigation. 
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Figure 1. Schematic of the mechanisms of RA isomer/CCA/NR pathways that facilitate 
mitochondrial biogenesis. A) NR-mediated pathway facilitating mitochondrial biogenesis. B) 
Exercise-mediated pathways facilitating mitochondrial biogenesis. C) RA-isomer mediated 
pathways leading to mitochondrial biogenesis. D) RA-isomer mediated activation of RARE 
receptors in mtDNA, leading to eventual mt protein translation.  
 
3.3 Retinoic Acid effect on Mitochondrial Biogenesis in Other Tissues 
The activity of retinoic acid on mitochondrial biogenesis has been characterized in tissues other 
than muscle.  When examining the effects of retinoic acid isomers on human liver tissue (HepG2 
cells), treatment with 1μM of ATRA led to elevations in PGC-1α, β and NRF-1 mRNA levels 
(72, 131), all associated with mitochondrial biogenesis. There was also a significant elevation in 
ATP levels in cell culture with ATRA treatment. In studies that looked at murine WAT cell 
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tissue, treatment with ATRA lead to significant elevations in oxygen consumption, an increase in 
Mitotracker Green staining , TFAM,  NRF-2, PGC-1β, PPARα mRNA and the mtDNA to 
nuclear DNA ratio (129). These effects also varied depending on the fat depot. Overall, the 
mitochondrial biogenesis augmentation in adipocytes appeared to be mediated via the PGC-1-
NRF-1-TFAM axis. In SH-SY5Y neuroblastoma cells, those treated with RA for 7 days showed 
increased and long strip-shaped mitochondria with well-developed mitochondria cristae, 
compared to immature and spherical mitochondria observed with vehicle treatment. SH-SY5Y 
cells treated with RAs led to elevations in PGC-1α, COX5a, and NRF-1, all mRNAs associated 
with mitochondrial biogenesis (141).  
4.0 Nicotinamide Riboside 
Nicotinamide Riboside (NR) is a nucleoside, which incorporates nicotinamide and ribose. NR is 
a precursor of nicotinamide adenine dinucleotide (NAD). It is present in yeast, bacteria, and 
mammals, and is a source of Vitamin B3 (28, 77, 105). Yeast-containing food products and milk-
derived products such as whey fractions have been reported to contain the nutrient, albeit in very 
small doses. The metabolic fate of NR in elevating NAD
+
 levels  in mammalian tissues was first 
investigated by Rowen and Kornberg in 1952 (28). This was further expanded on by the work of 
Charles Brenner (13, 130), who described the human nicotinamide riboside kinases (Nrk1 and 
Nrk2) as   potential players in mediating NR metabolism. Further research showed that this 
pathway is independent of nicotinamide metabolism, and that NR is a potent stimulator of NAD
+ 
production in several cultured mammalian cell types, including mouse and human cells. 
Increases in NAD
+
 were in some cases as high as 270% of controls (15). Together, this literature 
suggested that nicotinamide riboside has a unique metabolic pathway to synthesize NAD
+
 
independent of other studied Vitamin B3 compounds, and is very potent in enhancing NAD
+
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levels. NAD
+ 
is a key metabolite, used in basic energy metabolism processes such as glycolysis, 
the citric acid cycle, and mitochondrial electron transport. Previous literature on NR function has 
demonstrated that NR increases insulin sensitivity and induces mitochondrial biogenesis (28), 
and it exhibits neuroprotective effects in a mouse model of Alzheimer’s (28). In July 2013, 
nicotinamide riboside became available in supplement form with the brand name NIAGEN 
(Chromadex Incorporated, Irvine, California, USA).  
4.1 Nicotinamide Riboside Pathway 
NR has two potential pathways that it can participate in once it is taken up and metabolized by 
the cell. The first pathway is conversion into nicotinamide (NAM) via the action of purine 
nucleoside phosphorylase, followed by conversion of NAM into nicotinamide mononucleotide 
(NMN) by nicotinamide phosphoribosyl transferase (13, 90, 148).  The second pathway involved 
the direct conversion of NR into NMN by the action of nicotinamide riboside kinases 1 and 2 
(NRK1, 2). Both pathways lead to the synthesis of NMN, and from this point NMN is converted 
into NAD by NMN adenylyl transferase.  Once NAD
+
 is synthesized, it can then be utilized in 
NAD consumption processes by Sirtuins, CD38, and polyADPribosylpolymerases (PARPs) (15, 
142), also named the NAD consumers. The PARP pathway is activated in response to DNA 
damage (e.g. DNA strand breaks) and genotoxic stress, and it utilizes NAD
+
 to catalyze a 
reaction in which single strand breaks are repaired, while CD38 uses NAD
+
 to generate cADP-
ribose, a secondary messenger. Lastly, the sirtuin pathway is one of particular interest, with 
NAD-dependent deacetylase sirtuin-1 (SIRT-1) implicated in the deacetylation of PGC-1α, 
which would lead to an increase in PGC-1α activity (18, 45). However, members of PARP and 
the cADP-ribose synthase family have greater affinity for NAD
+
 compared to sirtuins. These 
PARPS critically impact intracellular NAD
+
 levels, and  the remaking concentration of NAD 
+ 
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determines whether there is sirtuin activation. Multiple studies also suggested that PARP activity 
constitutes the main NAD
+ 
catabolic activity, which forces cells to synthesize NAD
+
 from de 
novo or salvage pathways.  
4.2 Nicotinamide Riboside and Mitochondrial Biogenesis in Muscle 
The effects that NR exerts on elevating mitochondrial biogenesis have been characterized (77, 
90, 130, 142, 148), and involve NR increasing the NAD
+ 
levels in mammalian and yeast cells 
(95, 142), and in turn activating sirtuin 1 (SIRT1) in order to deacetylate PGC-1α. Mammals 
contain seven sirtuins (SIRT1–7), located in different subcellular compartments (22, 95). The 
nucleus contains SIRT1, SIRT6 and SIRT7, the cytosol contains SIRT2, and mitochondria 
contain SIRT3, SIRT4 and SIRT5. The sirtuins are implicated in a wide variety of biological 
functions including control of cellular metabolism and energy homeostasis, aging and longevity, 
transcriptional silencing, cell survival, proliferation, differentiation, DNA damage response, 
stress resistance, and apoptosis. Sirtuins are normally activated during situations of energy 
deprivation, and act as metabolic sensors of the cells, since their activity is coupled to changes in 
the cellular NAD
+
/NADH ratio (77).  NR first came into play as a potential agonist of 
mitochondrial biogenesis in research done by Canto et al (7, 18, 142). The goal of this study was 
to examine the avenue of increasing the overall bioavailability of NAD
+
 by supplementing with 
NR, rather than blocking NAD
+
 consumption pathways PARP and CD38, in order to promote a 
shift towards Sirtuin-mediated NAD
+ 
usage.  It was also found that NR supplementation dose-
dependently increased intracellular NAD
+
 levels in murine and human cell lines, with maximal 
effects at concentrations between 0.5 and 1 mM. In addition to increasing NAD
+
 levels, increases 
in mitochondrial content and function were also found with NR treatment, in brown adipose 
tissue as well as in muscle  (117). Additionally, NR has also been used to treat myopathy-
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induced mitochondrial deficits, as well as age-related disorders (77, 91). Reduced NAD
+
 levels 
have been reported in mitochondrial and age-related disorders, and NAD
+
 levels also decline 
with age (148, 150). 
5.0 Research Objectives 
Based on the Review of Literature provided here, the purpose of this thesis was: 
1) To examine the effects of retinoic acid isomers 9cisRA and ATRA on muscle cell 
mitochondrial biogenesis and autophagy-related proteins; 
2) To investigate how Chronic Contractile Activity and Retinoic Acid promote 
mitochondrial biogenesis, and if the combination of the two treatments elevates 
biogenesis to levels higher than either condition alone; 
3) To investigate how Retinoic acid interacts with a known agonist of mitochondrial 
biogenesis, Nicotinamide Riboside.  
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Abstract 
Exercise is well known to be a potent inducer of mitochondrial biogenesis, showing elevations in 
mitochondrial content and function. Two nutritional compounds, the Retinoic Acid (RA) isomers 
and Nicotinamide Riboside (NR), have shown promise in terms of inducing mitochondrial 
biogenesis, and NR has been established as a supplement that can be taken to bolster 
mitochondrial content. Retinoic acid have facilitated biogenesis in other tissues, but to date have 
not examined skeletal muscle. We examined the effects of retinoic acid on biogenesis, by using it 
concurrently with NR, and with CCA, a cell culture model of exercise. After 4 days of treatment, 
our findings show elevations in the mitochondrial-encoded proteins with RA isomer treatment, 
while the nuclear encoded proteins were unaffected.  NR elevated the nuclear encoded protein 
COX-IV, but had no effect on other nuclear proteins. In the RA isomer and CCA experiments, 
we observed elevations in COX I of ~3-fold with RA isomer treatment, while COX IV was 
augmented ~2-fold with CCA treatment. PGC-1α was also elevated with RA treatment by 2.2-
fold. The combination of RA isomer and CCA treatments led to augmentation of PGC1-1α, 
which was further elevated by 2.5-fold.  Interestingly Tfam was attenuated with RA treatment by 
0.68-fold in the RA and NR series of experiments, while only 9cisRA suppressed the precursor 
form in the RA and CCA series of experiments. We speculate that RA exerts its effects mainly 
on the mitochondrial genome, and can function to supplement the dominantly nuclear DNA 
adaptations of CCA.  
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Introduction 
Mitochondrial content in muscle tissue is regulated by a balance between breakdown 
(mitophagy) and synthesis (biogenesis). It is well established that exercise is a potent inducer of 
mitochondrial biogenesis in muscle, allowing for greater oxygen consumption and ATP 
generation (69, 76). Acute exercise creates an energy deficit and stimulates ATP turnover, 
leading to elevations in AMP, cytosolic Ca 
2+ 
flux, and ROS production (153). These processes 
lead to the activations of kinases such as AMPK, p38 MAPK, and CAMK, which are known to 
phosphorylate transcription factors, including a major regulator of mitochondrial biogenesis, 
PGC-1α (18, 35, 45, 63, 65, 67, 72, 87, 128, 134, 153). The recruitment of  PGC-1α leads to the 
coactivation of PPAR and NRF families of transcription factors, which regulate the transcription 
of multiple proteins responsible for  oxygen consumption and the biogenesis of the organelle (61, 
67, 109, 125). Once new mitochondria have been generated, they fuse to form larger reticular 
mitochondrial structures which serve to minimize diffusion distances and maximize ATP 
production (7, 23).   
 While the effects of chronic exercise on mitochondrial content and function are well 
known  (66), less information is available on the effects of possible nutrients that could facilitate, 
promote or synergize with exercise to produce a more pronounced effect on mitochondria. Such 
compounds could generate considerable scientific and commercial interest. The choice of 
nutrient to investigate may require a prior knowledge that it acts independently, or in cooperation 
with, the exercise signaling pathways. A derivative of Vitamin A called retinoic acid (RA) may 
facilitate mitochondrial biogenesis in a manner that appears partially distinct from that activated 
by exercise. RA isomers have been identified as potential agonists of mitochondrial biogenesis 
by studies that identified their ability to elevate mitochondrial content in adipocytes (129), 
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hepatocytes (96, 131) and neurons (144, 152). Retinoic acid is thought to target mitochondrial 
biogenesis through either ligand activation of the RXR-PPAR dimer, retinoic acid response 
element (RARE) sites found on nuclear and mtDNA, or indirect activation via kinase pathway 
phosphorylation of PGC-1α (153).  The majority of the mechanisms that promote mitochondrial 
biogenesis are focused on PGC-1α activation, which increases the transcription of NUGEMPs 
and elevated fatty acid oxidation. 
In addition to Vitamin A derivatives, we were intrigued by the potential activity of the 
derivative of Vitamin B3, nicotinamide riboside (NR), which operates via independent 
mechanisms. NR activates mitochondrial biogenesis through the NAD-Sirtuin pathway, which 
deacetylates and activates PGC-1α, launching a cascade of events that ends with the expression 
of nuclear genes encoding mitochondrial proteins (NUGEMPs) (94). It also provides higher 
levels of the electron acceptor molecule NAD
+,
 which functions to promote ATP generation. 
Indeed, NR has in turn been commercialized as Niagen ®, a NR salt that can be consumed as a 
supplement. However in combination with exercise, it appeared to negatively affect the 
performance in rats performing a swimming test (79), possibly due to a reduction in fatty acid 
oxidation which is required to sustain the energy for prolonged exercise bouts. In contrast, 
retinoic acid has been found to elevate fatty acid oxidation in C2C12 muscle cells (3).  We 
hypothesize that retinoic acid will have an adjunct effect on both CCA and NR, elevating 
biogenesis to a higher extent than either treatment alone through kinase-mediated PGC-1 
activation and/or RARE site activation. 
Thus, the primary objective of this study was to investigate the effects of RA isomers in 
myotubes, and the secondary objective was to examine how these RA isomers interact with NR 
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or chronic contractile activity (CCA), a cell culture model of exercise, to stimulate organelle 
biogenesis.  
Methods 
Cell culture. Passage 15 C2C12 murine skeletal muscle cells were plated and proliferated on 6- 
well plates in growth media (GM), which is composed of Dulbecco’s modified Eagle’s Medium 
(DMEM) that was infused with 10% fetal bovine serum and 1% penicillin-streptomycin (P/S) 
antibiotic. Cells were incubated at 37
o
C in 5% CO2.  Upon proliferation to 90-95% confluency, 
the growth medium was removed, and replaced with differentiation medium (DM (DMEM+ 1% 
p/s, 5% heat-inactivated horse serum)) in order to facilitate the differentiation of myoblasts into 
myotubes. The media was replaced daily. To investigate the effect of RA, DM containing 1μM 
of RA was added to 6-well plates containing myotubes for 4 days, with media replaced every 
24h in drug experiments in Protocol 1, or pre and post CCA bout in  Protocol 2. The appropriate 
dose was determined from previous research on mitochondrial biogenesis in other tissues, as well 
as dose-response studies. To investigate the effect of NR, DM containing 1mM of NR was added 
to 6-well plates. CCA plates were used in place of lids for the CCA-labelled cells, and cells were 
induced to contract over a 3h period. Cells were harvested 24h after the final CCA bout and/or 
nutrient delivery day.  
CCA. Myotubes were stimulated on the 5
th
 day of differentiation, as done in previous studies 
(31). Customized 6-well plate lids outfitted with two platinum wires per well were submerged 
into the media. The DM was replaced prior to stimulation and immediately after. For RA 
experiments, the DM was replaced with either DMSO-infused DM or RA-infused DM prior and 
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immediately after CCA. Electrical current was conducted for 3h a day (9V, 5Hz) with 21h 
recovery periods for a total of 4 days. Cells were collected 21h after the last CCA bout.  
Protein Extraction. Cells were washed with ice-cold PBS and then removed from the plates via 
trypsinization 21h after the last day of CCA/24h after last NR and RA treatment. Protein extracts 
were prepared by suspending the cells in lysate buffer that was supplemented with phosphatase 
inhibitors and protease inhibitor cocktail. Cells were then frozen in liquid nitrogen and thawed in 
a 37
o
C for 3 freeze-thaw cycles in order to lyse the cells. Samples were then centrifuged at 
16,000g at 4
o
C for 10 minutes, the pellets were discarded, and the supernatant fractions were 
collected and stored at -80
o
C for subsequent immunoblotting analysis.  
Immunoblotting. The protein concentration was quantified via Bradford Assay.  Thirty μg of 
protein per sample was separated via electrophoresis on 10-15% SDS-polyacrylamide gels. The 
proteins were then transferred (Mini Trans-blot electrophoretic transfer cell, Bio-Rad, 
Mississauga, Canada) onto nitrocellulose membranes. After transfer, the membranes were 
blocked with 5% skim milk for 1h, and were then probed overnight at 4
o
C with the appropriate 
primary antibodies. The full list of proteins and their respective antibodies are on Table 1. Blots 
were washed (3x5min) with wash buffer ( Tris-buffered saline-Tween-20, 25mM Tris+HCl(pH 
7.5), 1mM NaCl and 0.1% Tween-20), after which blots were incubated with the appropriate 
secondary antibody for 1h at room temperature.  A second 3x5min wash was performed, and 
blots were visualized with chemiluminescence using Clarity Western ECL Substrate (Bio-Rad) 
and exposed in an imager. Signals were quantified with ImageJ Software (NIH, Bethesda, MD, 
USA) Values were normalized to the appropriate loading control. 
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Statistical Analysis. All data are represented as means ± SEM. Comparisons between groups in 
Protocol 1 (Figure 1) experiments and Protocol 2 experiments (Figure 2) were made with 
unpaired t-tests and two-way ANOVA tests in Protocols 1 and 2, with the two factors being 
either RA and NR, or RA and CCA. The kinase experiments comparisons between conditions 
were made with one-way ANOVA tests. Analyses were made with GraphPad Prism 
7.0.Differences were considered significant if p<0.05 
 
 
 
 
 
 
 
 
30 
 
 
Figure 1. Protocol 1: the application of NR and RA isomers over 4 days post differentiation, in 
order to examine markers of mitochondrial biogenesis.  
 
Figure 2. Protocol 2: the application of RA isomers as an adjunct to CCA over 4 days post 
differentiation, in order to examine mitochondrial turnover.  
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Table 1. Western Blot Proteins of Interest 
Protein of 
Interest+ 
molecular weight 
Company 
Product 
No. 
Primary 
Concentration 
Secondary 
Concentration 
R=rabbit 
M=mouse 
Kinases 
(p)-p38 (38kDa) Cell Signalling 9211 1:1000 1:1000 R 
(t)-p38 (38 kDa) Cell Signaling 9212 1:1000 1:1000 R 
(p)- CAMK II 
(50kDa) 
Cell Signalling 3361 1:1000 1:1000 R 
(t) - CAMK II 
(50kDa) 
Cell Signalling 3362 1:1000 1:1000 R 
(p)-AMPK (62kDa) Cell Signaling 2532S 1:1000 1:1000 R 
(t)-AMPK (62kDa) Cell Signaling 2535S 1:1000 1:1000 R 
Mitochondrial Biogenesis 
COX I    (39kDa) Abcam Ab14705 1:500 4:2500 M 
COX IV (20kDa) Abcam Ab14744 1:250 1:750 M 
TFAM (24,28kDa) in house n/a 1:2500 1:3500 R 
Citrate Synthase 
(38kDa) 
Abcam Ab96600 1:1000 1:1000  R 
NRF-1 Rockland 200-401 1:1000 1:1000 R  
PGC-1α Millipore AB3242 1:1000 1:3000 R 
Loading Control 
Alpha-tubulin 
(50kDa) 
Calbiochem CP06 1:5000 1:1000  R 
GAPDH (37kDa) Abcam Ab8245 1:100,000 1:5000 M 
Autophagy 
LC3 Cell Signalling 2775 1:500 1:1000 R 
P62 Sigma-Aldrich P0067 1:6000 1:4000 M 
Beclin Cell Signalling 3738S 1:1000 1:1000 R  
Protein Import Machinery + Chaperones 
Tim23 BD Biosciences 611222 1:1000 1:3000 R 
Tom 40 Santa Cruz sc-11414 1:1000 1:3000 R 
mtHsp60 
Enzo Life 
Sciences 
ADI-SPA-
806 
1:1000 1:1000 M 
mtHsp70 
Enzo Life 
Sciences 
ADI-SPA-
825 
1:1000 1:1000 M 
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Results 
Retinoic Acid treatment elevated mt-DNA derived proteins, but not nuclear derived proteins that 
are associated with mitochondrial biogenesis. C2C12 myoblasts were treated with either vehicle, 
RA isomers, NR or the combination of RA isomers and NR. COX-I, a mitochondrially-encoded 
subunit of Complex IV increased 3.1-fold in 9cisRA-treated cells, 2.8- fold in ATRA-treated 
cells, and by 3.7-fold  and 3.9-fold in NR+9cisRA/NR+ATRA respectively (P<0.05; Figure 3.C). 
The nuclear-encoded COX IV subunit was elevated only with NR treatment, while the addition 
of the RA isomers led to an interaction effect that negated the elevation seen with NR alone.  The 
transcriptional co-regulator of mitochondrial biogenesis PGC-1α was unaltered by RA isomers 
and NR treatments. Lastly, citrate synthase, a key component of the Krebs cycle, was also 
unperturbed by treatments with RA isomers NR.  
RA treatment lowers the expression of Tfam protein. Treatment with RA resulted in decreases in 
the precursor Tfam protein by 32%, and the mature Tfam protein expression levels by 27% 
(P<0.05; Figure 3G, H). The fraction of mature Tfam protein relative to the total Tfam remained 
unaltered.  
RA elevated the protein levels of Tom40, but not Tim23, while NR led to elevations in mtHsp70. 
Tom40, an outer mitochondrial membrane transporter, was elevated by 70-72% with RA 
treatment (P<0.05; Figure 4C). NR treatment alone led to an elevation in protein levels of the 
chaperone mtHsp70 by 52% (P<0.05; Figure 4D), while the addition of RA isomers led to an 
interaction effect that nullified NR-mediated increase.  Tim23 was unaltered by treatment with 
either nutrient. 
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RA elevated mtDNA-encoded mitochondrial proteins, but only some of the nuclear encoded 
proteins. C2C12 cells were treated with RA and 3h of CCA over 4 days post-differentiation.  
COX-I protein levels increased 2.0-2.4 fold with RA treatment alone, and ~3-fold elevations 
were seen in conjunction with CCA (Figure 5B; P<0.05). COX-IV protein levels were unaltered 
with RA treatment, but CCA treatment led to elevations between ~2-fold in all CCA conditions 
regardless of the RA isomers (Figure 5C; P<0.05). The master co-activator PGC-1α protein 
levels were elevated with RA treatment by 2.2-fold, while the combination of RA and CCA led 
to elevations between 2.4- 2.5 fold (Figure 5F; P<0.05).There were no significant alterations in 
protein levels of nuclear-encoded Citrate Synthase (Figure 5D) and the precursor Tfam protein 
form (Figure 5G) and mature Tfam form (Figure 5H).  
RA and CCA elevated the protein levels of Tom40, but not Tim23 or the chaperones mtHsp60,70. 
RA and CCA treatment both had a main effect on Tom40 protein levels (2-fold and 1.5-fold 
respectively), while only RA treatment alone had a main effect leading to elevated Tim23 levels 
(post-hoc revealed ATRA was main reason for this effect,a 1.7-fold increase).   
Retinoic acid treatment did not alter protein levels of autophagy-related proteins. The protein 
levels of p62, an adaptor protein, remained unaltered both with RA treatment alone, and in 
conjunction with CCA. The autophagosome protein LC3 I, which is lipidated to its mature form 
LC3 II, was also unaltered with RA and CCA treatments. The autophagy-related protein Beclin, 
was also unaltered with RA and CCA treatments.  
Retinoic acid does not activate the kinase pathways in C2C12 myotubes.  Treatment of C2C12 
cells with 1μM RA for 30min did not result in increases of total nor phosphorylated AMPK, p38 
MAPK or CAMK II kinases. 
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Figure 3. Treatment of C2C12 myotubes with retinoic acid and nicotinamide riboside results in 
increases in mt-DNA derived mitochondrial proteins. (A). Representative Western Blots and 
graphical quantifications of : (B) COX-I, (C) COX-IV, (D) Citrate Synthase, (E) PGC-1α.  (F) 
Representative Western Blots and graphical quantifications (G) Tfam precursor, (H) Tfam 
mature (I) Mature percentage of Total Tfam.  Data are registered as mean ±SEM and are 
measured in arbitrary units/%. (¶:  main effect of RA, *: Veh vs NR, **: interaction effect of NR 
+RA, P<0.05 vs vehicle; n=4-7).  
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Figure 4.  Treatment of C2C12 myotubes with retinoic acid and nicotinamide riboside resulted in 
increases in import protein Tom40 expression, but only nicotinamide riboside led to chaperone 
elevation. A).Representative Western Blots and graphical quantifications of; (B) Tim23, (C) 
Tom40, (D) mtHsp70.  Data are registered as mean ±SEM and are measured in arbitrary units. 
(¶: main effect of RA, *: Vehicle vs NR, **: interaction effect of NR +RA, P<0.05 vs vehicle; 
n=4-5).  
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Figure 5. Treatment of C2C12 myotubes with retinoic acid and CCA resulted in increases in 
mtDNA- derived mitochondrial proteins, but not nuclear-derived mitochondrial proteins. A) 
Representative Western Blots and graphical quantifications of; (B) COX-I, (C) COX-IV, (D) 
Citrate Synthase. (E) Representative Western Blots and graphical quantifications of: (F) PGC-1α, 
(G) Tfam Precursor, (H) Tfam Mature. Data are registered as ±SEM and are measured in a 
rbitrary units. (¶: main effects of RA, : main effect of CCA,* Veh vs CCA+ 9cisRA,  P<0.05 vs 
vehicle; n=6-13). 
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Figure 6. Treatment of C2C12 myotubes with retinoic acid and CCA had no effect on autophagy 
in C2C12 cells. (A) Representative Western Blots and graphical quantifications of: (B) p62, (C) 
LC3II/I ratio, (D) Beclin. Data are registered as mean±SEM (*,:veh vs 9cisRA+CCA) (n= 4-8).  
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Figure 7. Treatment of C2C12 myotubes with retinoic acid and CCA resulted in elevations in the 
import proteins Tim23 and Tom40, but did not alter mt-chaperone protein expression. (A) 
Representative Western blots and graphical quantifications of: (B) Tim23, (C) Tom40. (D) 
Representative Western blots and graphical quantifications of: (E) mtHsp60, (F) mtHsp70. Data 
are registered as mean ±SEM and are measured in arbitrary units. (¶: main effect of RA, ,:main 
effect of CCA, *: Vehicle vs ATRA; n=4-11). 
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Figure 8. Retinoic acid treatment for 30 minutes did not elevate kinase activity in C2C12 cells. 
Treatment of C2C12 myotubes with 1μM RA did not result in elevations in kinase activity. (A) 
Representative Western Blots and graphical quantifications of (B) p-AMPK/t-AMPK ratio, (C) 
p-p38/t-p38 ratio (D)p-CAMKII/t-CAMKII. Data are registered as mean ±SEM and are 
measured as a ratio of p/t protein levels (n=4-6).  
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Discussion 
Mitochondria are organelles responsible for providing energy for cellular functions in the form 
of ATP. Mitochondria are plastic in nature, and can be stimulated to divide and expand their 
networks in muscle tissue.  Exercise has been well established as a potent inducer of 
mitochondrial biogenesis network expansion, while also leading to an increase in breakdown of 
dysfunctional mitochondria (55, 67). This process is mediated, in part, by exercise-induced 
increases in the activity of the master regulator PGC-1α (45). The activation of PGC-1α can be 
targeted in several ways, one of which is deacetylation, and the other being phosphorylation 
(153).  In addition to exercise, several nutritional approaches that have the potential to have the 
same effects have emerged, which include resveratrol (94) and NR.  Resveratol in particular has 
been shown to exhibit synergistic effects on mitochondrial biogenesis in C2C12 myotubes when 
combined with CCA which is why we were interested to see if other compounds could also 
synergize with CCA. NR treatment resulted in elevations of mitochondrial biogenesis proteins in 
C2C12 cells (89,91), but due to NR’s overlap with CCA, and  RA’s numerous potential pathways 
that are separate from CCA, we felt that RA would be a better candidate for  additivity and/or  
synergy studies.  
Retinoic acid isomers have been shown to activate mitochondrial biogenesis, containing 
some mechanisms that are independent from the effects of NR and CCA, and this led to our 
interest in examining their potential for synergy. RA isomers operate by ligand activation of the 
RAR and RXR receptors, which represent the retinoic acid response elements (RARE), found in 
both the nuclear and mitochondrial genome. RA isomer treatment elevates mitochondrial 
biogenesis in tissue such as adipocytes (129), liver (97, 131) and neurons (144). However, the 
effects of RA isomers on myotube mitochondria are not fully understood. Thus, we treated C2C12 
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myotubes with a dose of 1µM, which is a supra-physiological dose compared to serum levels 
(3.8 to 5.pM) found in mice. The dose used in our studies has been used in previous literature in 
order to differentiate cells (24, 102), and was the maximal dose that did not elicit negative effects 
(86). RA did not lead to changes in PGC-1α in the RA and NR synergy experiments. In addition 
to this observation, RA treatment led to elevations in the mtDNA encoded COX-I subunit of 
Complex IV, which corroborates previous findings in rat testes (50). RA isomers did not impact 
the expression of the nuclear-derived subunit COX-IV, which suggested to us that the effects of 
RA on the ETC may be specific to mtDNA-encoded proteins.  
With RA treatment, we observed decreases in Tfam protein levels, with decreases present 
in both the cytosolic precursor form and the matrix-destined mature form. This is contrary to 
previous findings (129), which found increases in Tfam in adipocytes. We examined other 
literature with regards to RA and/or Tfam regulation, and found that RA may potentially prevent 
Tfam from binding to mtDNA via the ERK-2 pathway activation (10).  This could lead to Tfam 
being unable to bind to LSP and HSP on the mtDNA (Figure 1). Tfam’s role in the mitochondria 
is potentially partially fulfilled by the binding of RA to the RARE site just downstream at the 
hormone response element site (HRE), activating HSP (heavy strand promoter) transcription, as 
COX-I was elevated despite Tfam being attenuated. Low levels of Tfam have been shown to be 
sufficient for LSP (light strand promoter) activation (51), suggesting that transcription could 
occur with low levels of the protein. We speculate that the block in Tfam activation and the RA 
activation of HSP transcription downstream of Tfam’s binding site could lead to lower levels of 
Tfam in the cell via RARE site repression, as RARE sites without ligand activation serve as 
repressors (121)  
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 Due to the changes we observed in Tfam, we investigated whether the protein import 
system that facilitates Tfam entry into the matrix was also affected by RA. Treatment with RA 
resulted in elevations of the Tom40 outer membrane channel, but did not affect Tim23 a 
component of the inner membrane. However, we saw no changes in the chaperone proteins 
mtHsp60 and 70 with RA treatment. 
RA isomers are well known for their ability to facilitate autophagy in neurons, liver 
tissue, and cancer cells like leukemia (103). Treatment of leukemic NB4 neural cells with 1μM 
of ATRA resulted in an increase in LC3 II/I levels, and this was abolished upon the addition of 
chloroquine, an autophagy inhibitor. Surprisingly, we did not observe the elevations in 
autophagy that were seen in previous research. This may be due to the difference in tissue type, 
treatment time, or the lower doses of RA used in our experiments (1µM), while autophagy 
papers mostly had doses in the 5-10μM range, and examined different cell lines.  
Nicotinamide Riboside (NR) treatment in myotubes demonstrated a marked increase in 
COX-IV protein levels, while the addition of RA led to an interaction effect that attenuated the 
increase. NR did not affect citrate synthase or Tfam protein levels, and had no impact on 
mitochondrial-encoded proteins such as COX-I. NR treatment had no effect on the protein 
import machinery, but did result in an elevation in the chaperone mtHsp70, while the addition of 
RA resulted in an interaction that inhibited the elevation in mtHsp70. 
We have previously demonstrated that our cell culture model of exercise, CCA, resulted 
in significant elevations in mitochondrial biogenesis, indicated by elevations in PGC-1α, COX 
IV, and Tfam (133).  Similarly, our results with CCA (alone) demonstrated elevations in COX-
IV, but no significant impact on Tfam protein levels. We speculate that this may be due to higher 
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cell passages used in this experiment, as higher passages do not appear to be as responsive as 
younger passages used in our previous studies. This phenomenon is something we did not 
observe until now.  The interaction of CCA and RA markedly elevated PGC-1α level, exhibiting 
main effects of CCA and of RA treatment. In this set of experiments, we saw RA treatment led to 
elevation of the protein levels of PGC-1α, something not seen Protocol 1, and something we 
believe to be a consequence of the longer exposure to retinoids in Protocol 2, in addition to 
Protocol 1 containing 4 treatments of retinoic acid compared to the 8 treatments in Protocol 2.  
When examining the protein levels of COX-I, there was a marked elevation with RA treatment, 
but no effect of CCA, which was similar to RA’s effect in Protocol 1 experiments, while the 
CCA elevated COX-IV protein levels. In this case, CCA with RA supplementation had no 
bearing on COX-IV protein levels, which suggests the two pathways do not interfere with each 
other.  
 Although there was total Tfam level suppression in the NR and RA experiments, the 
combination of RA and CCA resulted in a significant reduction of Tfam in 9cisRA, but not 
ATRA treated cells. Due to the difference in protocol and exposure times to RA, it is possible 
that some of the RARE site repression may have been attenuated due to a longer exposure to RA, 
and a higher possibility of RA binding to RAR/RXR dimers that could be repressing Tfam 
transcription.  We examined NRF-1, which is responsible for transcribing Tfam, and found that it 
was not altered with RA treatment, suggesting it is not the mechanism responsible for the 
attenuation in Tfam levels.   
Due to the changes observed in Tfam, we also examined the import machinery and 
chaperone systems in the mitochondria. We observed elevations in Tim23, with ATRA 
treatment, but not with 9cisRA or CCA treatments, while Tom40, the outer membrane machinery 
46 
 
protein, was elevated with both isomers, as well as with the CCA treatment. There was no effect 
on the major chaperones that carry Tfam to the mtDNA, suggesting RA acts on the import 
channels alone.  
 Lastly, we examined whether RA activation of PGC-1α is mediated by the kinases 
typically activated during exercise, which include MAPK p38, AMPK, CAMK II (153). 
Contrary to our hypothesis, and to the elevations of CAMKII, p38 MAPK and AMPK seen in 
other literature (6, 18, 63, 73, 153), we did not observe any elevations in phosphorylated 
(activated) to total kinase ratio, which suggests that RA does not lead to kinase activation in 
skeletal muscle under the conditions  in this study. We believe the reason we were unable to see 
activation may be due to the dose we have used of 1μM instead of the 10μM dose in another 
paper that examined RA.  
 In summary, it appears that our primary objective was partially met. RA isomers, given 
the conditions of this study, primarily influence the transcription of mtDNA proteins such as 
COX-I, while having no effect on nuclear encoded mitochondrial proteins. This suggests that RA 
isomers may indeed interact with mtDNA through RAR/RXR receptor activation.  We found that 
RA attenuated total Tfam production, while having no effect on any other mitochondrial marker 
of biogenesis. Further investigation will be needed in the future studies in order to investigate the 
interaction between RA, and how activating retinoid receptors on Tfam promoters can attenuate 
its transcription and translation. We show here that the import pathways of the mitochondria 
were augmented, specifically in the case of the outer membrane, which suggests the decreases in 
Tfam were not post-translational.  Contrary to our hypothesis, RA did not facilitate the activation 
of PGC-1α through increases in kinase activation, which include AMPK, p38 and CAMKII. RA 
may target PGC-1α activation and/or transcription through different pathways, having the 
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potential to facilitate PGC-1α transcription and eventual translation through PKA/cAMP/CREB 
pathway activation (88), and MEF2C activation (114), which have been shown in neural and 
cardiac tissue respectively. We believe that some limitations to our study are the lack of a 
functional assessment of mitochondria, such as measuring oxygen consumption with a Clark 
electrode. Another limitation was the lack of a secondary method to measure mitochondrial 
content such as confocal microscopy combined with a mitochondrial dye, which could serve to 
strengthen our finding of increased mitochondrial content. Overall, our study shows that while 
RA and CCA are not synergistic, they have complimentary effects, targeting different facets of 
mitochondrial biogenesis, and highlight the potential of adequate Vitamin A supplementation to 
assist in metabolic health. 
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Table 2: A summary of the statistically significant effects of RA isomers and NR.on 
mitochondrial proteins with Protocol 1.  
Protocol 1 Vehicle 9cisRA ATRA NR 9cisRA+NR ATRA+NR 
Mt-DNA 
proteins - COX-I↑ COX-I↑ - COX-I↑ COX-I↑ 
N-DNA 
proteins - Tfam↓ Tfam↓ COX-IV↑ Tfam↓ Tfam↓ 
PGC-1α - - - - - - 
Import 
Proteins - Tom40↑ Tom40↑ - Tom40↑ Tom40↑ 
Table 3. A summary of the statistically significant effects of RA and CCA on mtDNA and nuclear 
encoded  mitochondrial proteins with Protocol 2. 
Protocol 2  Vehicle 9cisRA ATRA CCA 9cisRA+ 
CCA ATRA+ CCA 
Mt-DNA 
Protein - COX-I↑ COX-I↑ - COX-I↑ COX-I↑ 
N-DNA 
Protein - Tfam↓ - 
COX-IV↑ 
Tom40↑ 
Mature 
Tfam↓ 
COX-IV↑ 
COX-IV↑ 
PGC-1α - ↑ ↑ ↑ ↑ ↑ 
Import 
Proteins - Tom40↑ Tom40↑ - Tom40↑ Tom40↑ 
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Figure 9. RA isomers can potentially exert partial mtDNA transcription.  Adapted from 
Berdanier et al (13),  Everts et al (42). Retinoic Acid is able to bind to the HRE (Hormone 
Response Elements) of the mitochondrial DNA loop, and facilitate transcription of the heavy 
strand. RA isomers. This could potentially initiate mtDNA transcription by binding to the 
promoter region RXR and RARE sites. The arrows indicate transcription and replication start 
sites. Less is known about whether or not binding at the HRE-1 location can also facilitate 
transcription of the light strand.   
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Future Work 
1) Assessing the functionality of the mitochondria post CCA/RA/NR treatment would give a 
more complete picture of the mitochondrial quality and add depth to our work. Previous 
work from our lab has examined the oxygen consumption of cells treated with resveratrol 
(94), however my measurements of respiration with the Clark electrode were not 
successful. To this point, we have established that there is a higher level of  selected 
mitochondrial proteins post- RA and CCA treatment, however measuring the oxygen 
consumption rate (OCR) and the Extracellular acidification rate (ECAR) with the new 
Seahorse© instrument could tell us the metabolic profile of the mitochondria and whether 
or not shifts towards fatty acid oxidation have occurred.  
2) In order to examine how the functions of Tfam and RA may overlap in the mtDNA 
genome, a Tfam knockdown experiment with RA treatment may give insight into the 
interplay between RA and Tfam on mtDNA transcription. Knockout experiments are not 
viable (107), therefore a siRNA knockdown of Tfam, followed by RA treatment and 
measurement of mtDNA-encoded proteins will elucidate the interplay between the two.  
3) To date, we have found that RA facilitates the translation of PGC-1alpha via kinase-
independent activity, as none of the three major kinases have been elevated with RA 
treatment. The CREB and MEFC2 pathways are implicated in the transcription of PGC-
1α (88, 114) but our study has not explored them as possible avenues of the facilitation of 
PGC-1α transcription and eventual translation. Repetition of these experiments, followed 
by nuclear/cytosolic separation and analysis of PGC-1α levels would give us insight on 
the activation status with RA treatment.  
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4) Lastly, it would be beneficial to examine RA treatment in-vivo, and whether or not the 
effects seen in muscle cell tissue carry over into live animals since RA is implicated in 
the function of other major tissues in the body. Examining RA treatment of diabetic mice 
in conjunction with exercise would allow us to further elucidate the fatty acid oxidation 
and glucose handling effects, the amelioration of diabetic symptoms seen in mice with 
RA treatment (14, 17, 151), and lastly, mitochondrial turnover. In conclusion, examining 
RA treatment in the whole system would deepen our understanding of RA and how it 
interacts with exercise in order to impact metabolism. A  dose-response study would also 
allow us to see if higher RA concentrations would lead to augmented effects.    
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APPENDIX A- DATA AND STATISTICAL ANALYSIS 
 
 
 
 
 
 
 
 
 
 
 
 
65 
 
NR+ RA: COX-I 
 
 
 
 
 
 
 
 
 
 
 
 
Veh 9cisRA ATRA NR 9cisRA+NR ATRA+NR
N1 0.15304 0.541094 0.504779 0.254833 0.57775001 0.7083537
N2 0.182104 0.506663 0.51283 0.294425 0.68687503 1.22475192
N3 0.126158 0.543935 0.258515 0.306003 0.53358235 0.54806303
N4 0.191065 0.648129 0.364542 0.126387 0.44693767 0.31939969
N5 0.231709 0.496398 0.99906 0.465955 1.12436456 0.8459956
N6 0.476569 1.18528 1.30329 0.573802 1.54441147 1.26199188
Two-way ANOVA Ordinary
Alpha 0.05
Source of Variation % of total variationP v lue P value summarySignificant?
Interaction 0.1166 0.9721 ns No
Nicotinamide Riboside 3.928 0.1775 ns No
Retinoic Acid 34.17 0.0014 ** Yes
ANOVA table SS DF MS F (DFn, DFd)P value
Interaction 0.005656 2 0.002828 F (2, 30) = 0.02831P = 0.9721
Nicotinamide Riboside 0.1905 1 0.1905 F (1, 30) = 1.907P = 0.1775
Retinoic Acid 1.657 2 0.8285 F (2, 30) = 8.295P = 0.0014
Residual 2.996 30 0.09988
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NR+ RA: COX-IV 
 
 
 
 
 
Veh 9cisRA ATRA NR 9cisRA+NR ATRA+NR
N1 0.457142 0.642972 0.951201 1.246299 0.81041089 0.71983949
N2 0.409607 0.832108 0.786634 1.545588 0.58313244 0.40666336
N3 0.569781 1.152477 0.761304 1.564983 1.00670309 1.01947244
N4 1.524163 1.438776 1.195963 1.377011 1.23826638 0.33102603
N5 0.586168 0.639863 0.87964 0.616566 0.7520418 0.99781544
N6 1.023322 1.142173 1.336457 1.25046 1.54244624 1.11874506
Two-way ANOVA Ordinary
Alpha 0.05
Source of Variation % of total variationP v lue P value summarySignificant?
Interaction 18.06 0.0427 * Yes
Nicotinamide Riboside 1.975 0.3879 ns No
Retinoic Acid 2.786 0.5875 ns No
ANOVA table SS DF MS F (DFn, DFd)P value
Interaction 0.8209 2 0.4105 F (2, 30) = 3.510P = .0427
Nicotinamide Riboside 0.08977 1 0.08977 F (1, 30) = 0.7677P = 0.3879
Retinoic Acid 0.1266 2 0.06331 F (2, 30) = 0.5414P = 0.5875
Residual 3.508 30 0.1169
T-Test
Column B NR
vs. vs.
Column A Veh
Unpaired t test
P value 0.0497
P value summary *
Significantly different? (P < 0.05)Yes
One- or two-tailed P value?Two-tailed
t, df t=2.232 df=10
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NR+ RA: Tfam Precursor 
 
 
 
 
 
 
 
 
 
 
 
Veh 9cisRA ATRA NR 9cisRA+NR ATRA+NR
N1 2.005991 1.546914 1.477321 2.045553 1.32208547 1.40815239
N2 2.0322 1.012301 1.269745 1.862169 1.65299204 1.69414199
N3 0.880844 0.554427 0.506461 0.962822 0.62417582 0.70872326
N4 1.658563 1.439058 1.329961 1.709828 1.23435246 0.75968504
N5 1.647743 1.277239 1.145922 1.49582 0.73785713 0.53289672
N6 1.71516 0.992077 0.90351 1.471908 1.16783449 1.28601735
N7 1.962612 0.958215 1.207745 1.974368 0.89291242 1.07365801
Two-way ANOVA Ordinary
Alpha 0.05
Source of Variation % of total variationP v lue P value summarySignificant?
Interaction 0.03153 0.9908 ns No
Nicotinamide Riboside 0.2425 0.708 ns No
Retinoic Acid 38.46 0.0002 *** Yes
ANOVA table SS DF MS F (DFn, DFd)P value
Interaction 0.002541 2 0.001271 F (2, 36) = 0.009264P = 0.9908
Nicotinamide Riboside 0.01955 1 0.01955 F (1, 36) = 0.1425P = 0.7080
Retinoic Acid 3.1 2 1.55 F (2, 36) = 11.30P = .0002
Residual 4.938 36 0.1372
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NR+ RA: Tfam Mature 
 
 
 
 
 
 
 
 
 
 
 
Veh 9cisRA ATRA NR 9cisRA+NR ATRA+NR
N1 1.198509 0.95097 0.7803 0.958235 1.21161235 0.83697589
N2 1.397873 0.66769 0.714747 1.052157 1.41134266 1.2130195
N3 0.835355 0.498836 0.507414 0.694169 0.63565718 0.64524955
N4 1.805714 1.217779 1.215895 2.006747 1.14927241 1.04371961
N5 1.925347 1.310866 1.223174 2.125797 0.94482003 1.0369291
N6 0.92774 1.033342 0.64574 1.108736 1.07263314 1.3221273
N7 1.415701 1.026604 1.133475 1.650449 1.25898101 1.20834736
Two-way ANOVA Ordinary
Alpha 0.05
Source of Variation % of total variationP v lue P value summarySignificant?
Interaction 0.7066 0.8468 ns No
Nicotinamide Riboside 1.83 0.3585 ns No
Retinoic Acid 21.31 0.0118 * Yes
ANOVA table SS DF MS F (DFn, DFd)P value
Interaction 0.04266 2 0.02133 F (2, 36) = 0.1670P = 0.8468
Nicotinamide Riboside 0.1105 1 0.1105 F (1, 36) = 0.8650P = 0.3585
Retinoic Acid 1.287 2 0.6433 F (2, 36) = 5.038P = 0.0118
Residual 4.597 36 0.1277
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NR+ RA: Citrate Synthase 
 
 
 
 
 
 
 
 
 
 
 
 
Veh 9cisRA ATRA NR 9cisRA+NR ATRA+NR
N1 0.319858 0.447458 0.368228 0.444736 0.62518472 0.43879668
N2 0.254284 0.421712 0.459736 0.45608 0.71202845 0.59223581
N3 0.910008 1.435779 1.367846 1.225986 1.06348964 1.07570279
N4 1.119856 1.577323 1.372748 1.329589 1.7367088 1.75505815
N5 2.338919 2.730033 2.53469 3.031815 3.20635817 2.81862661
N6 3.215384 3.501194 2.918528 3.381289 3.16252489 3.55166021
Two-way ANOVA Ordinary
Alpha 0.05
Source of Variation % of total variationP v lue P value summarySignificant?
Interaction 0.1694 0.9746 ns No
Nicotinamide Riboside 0.7001 0.6476 ns No
Retinoic Acid 0.6429 0.907 ns No
ANOVA table SS DF MS F (DFn, DFd)P value
Interaction 0.07382 2 0.03691 F (2, 30) = 0.02579P = 0.9746
Nicotinamide Riboside 0.3051 1 0.3051 F (1, 30) = 0.2133P = 0.6476
Retinoic Acid 0.2802 2 0.1401 F (2, 30) = 0.09792P = 0. 070
Residual 42.92 30 1.431
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NR+ RA: PGC-1α 
 
 
 
 
 
 
 
 
 
 
 
 
 
Veh 9cisRA ATRA NR 9cisRA+NR ATRA+NR
N1 2.10118 2.664426 2.694689 1.874454 1.90043027 1.91843865
N2 1.733033 1.873163 1.77884 1.858456 2.170215 2.41581329
N3 1.186741 1.432181 1.117252 2.227577 1.81343415 1.79664782
N4 1.681099 2.644453 2.622733 2.149885 1.89705589 2.57604003
Two-way ANOVA Ordinary
Alpha 0.05
Source of Variation % of total variationP v lue P value summarySignificant?
Interaction 7.08 0.4873 ns No
Nicotinamide Riboside 1.061 0.6415 ns No
Retinoic Acid 6.713 0.5051 ns No
ANOVA table SS DF MS F (DFn, DFd)P value
Interaction 0.3175 2 0.1588 F (2, 18) = 0.7484P = 0. 873
Nicotinamide Riboside 0.04758 1 0.04758 F (1, 18) = 0.2243P = 0.6415
Retinoic Acid 0.301 2 0.1505 F (2, 18) = 0.7095P = 0. 051
Residual 3.819 18 0.2121
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NR+ RA: Tim23 
 
 
 
 
 
 
 
 
 
 
 
 
Veh 9cisRA ATRA NR 9cisRA+NR ATRA+NR
N1 0.455771 1.615091 1.020756 0.343741 0.56744315 0.61256319
N2 0.359669 1.121597 1.179078 0.79646 0.38719307 0.7239974
N3 0.842077 1.00708 0.754723 0.626519 0.86112557 0.79627938
N4 0.560493 0.393416 0.79218 0.770954 1.26856704 0.82337038
N5 0.889755 1.01876 1.241682 1.115081 1.57939356 0.98620795
Two-way ANOVA Ordinary
Alpha 0.05
Source of Variation % of total variationP v lue P value summarySignificant?
Interaction 4.094 0.5467 ns No
Nicotinamide Riboside 1.032 0.5815 ns No
Retinoic Acid 15.54 0.1168 ns No
ANOVA table SS DF MS F (DFn, DFd)P value
Interaction 0.1305 2 0.06523 F (2, 24) = 0.6192P = 0.5467
Nicotinamide Riboside 0.03288 1 0.03288 F (1, 24) = 0.3122P = 0.5815
Retinoic Acid 0.4953 2 0.2476 F (2, 24) = 2.351P = 0.1168
Residual 2.528 24 0.1053
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NR+ RA: Tom40 
 
 
 
 
 
 
 
 
 
 
 
 
 
Veh 9cisRA ATRA NR 9cisRA+NR ATRA+NR
N1 0.411675 1.230645 0.755256 0.409733 0.78722211 0.7715069
N2 0.460717 0.86972 1.201367 0.597706 0.79719072 1.00960683
N3 0.777217 0.796156 0.967835 0.959866 1.73427318 1.24222167
N4 1.143015 1.153965 1.276153 0.894407 1.36742336 1.19698556
Two-way ANOVA Ordinary
Alpha 0.05
Source of Variation % of total variationP v lue P value summarySignificant?
Interaction 1.223 0.8515 ns No
Nicotinamide Riboside 0.9131 0.6285 ns No
Retinoic Acid 30.02 0.037 * Yes
ANOVA table SS DF MS F (DFn, DFd)P value
Interaction 0.02928 2 0.01464 F (2, 18) = 0.1622P = 0.8515
Nicotinamide Riboside 0.02187 1 0.02187 F (1, 18) = 0.2423P = 0.6285
Retinoic Acid 0.7189 2 0.3595 F (2, 18) = 3.982P = 0.0370
Residual 1.625 18 0.09026
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NR+ RA: mtHsp70 
 
 
 
 
 
 
Veh 9cisRA ATRA NR 9cisRA+NR ATRA+NR
N1 0.720919 0.76442 1.080749 0.952431 0.57468624 0.67108515
N2 0.59946 0.656441 0.670942 1.130639 0.59434768 0.53729659
N3 0.521339 0.637272 0.675036 0.9645 0.77722957 0.83952721
N4 0.838671 0.828196 0.69259 0.865215 0.97621958 1.16551318
Two-way ANOVA Ordinary
Alpha 0.05
Source of Variation % of total variation
Interaction 14.26 P value P value summarySignificant?
Nicotinamide Riboside 9.699 0.1927 ns No
Retinoic Acid 5.002 0.1344 ns No
0.5421 ns No
ANOVA table SS
Interaction 0.1138 DF MS F (DFn, DFd)P value
Nicotinamide Riboside 0.07737 2 0.05688 F (2, 18) = 1.807P = 0.1927
Retinoic Acid 0.0399 1 0.07737 F (1, 18) = 2.458P = 0.1344
Residual 0.5667 2 0.01995 F (2, 18) = 0.6337P = 0.5421
T-Test
Column B NR
vs. vs.
Column A Veh
Unpaired t test
P value 0.0134
P value summary *
Significantly different? (P < 0.05)Yes
One- or two-tailed P value?Two-tailed
t, df t=3.463 df=6
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CCA+ RA: COX-I 
 
 
 
 
 
 
 
Veh 9cisRA ATRA CCA 9cisRA+CCA ATRA+CCA
N1 0.252742 0.514703 0.607541 0.206468 0.5094314 0.5091134
N2 0.273371 0.609604 0.429473 0.357093 1.03406 1.232016
N3 0.456783 0.796754 0.917869 0.710399 1.183333 1.280402
N4 0.126412 0.328711 0.598258 0.310621 0.7023895 0.7685578
N5 0.342989 0.576279 0.700594 0.404698 0.6317692 0.5046039
N6 0.750224 1.464645 2.070752 0.78129 1.464752 2.768845
N7 1.67299 1.760236 2.98035 1.532209 2.405668 3.094999
N8 0.270368 0.479026 0.569366 0.263079 0.6699001 0.7915437
N9 0.271515 0.819358 0.867048
N10 0.402684 1.261479 0.897823
N11 0.280367 0.651189 0.589426
N12 0.747248 1.617327 1.645698
N13 1.010448 1.66364 1.805154
N14 0.353691 0.685385 0.780494
N15 0.616829 0.874567 0.688848
Two-way ANOVA Ordinary
Alpha 0.05
Source of Variation % of total variationP v lue P value summarySignificant?
Interaction 0.538 0.8125 ns No
cca 1.334 0.3133 ns No
drug 16.88 0.0026 ** Yes
ANOVA table SS DF MS F (DFn, DFd)P value
Interaction 0.1589 2 0.07944 F (2, 63) = 0.2083P = 0.8125
cca 0.394 1 0.394 F (1, 63) = 1.033P = 0.3133
drug 4.984 2 2.492 F (2, 63) = 6.535P = 0.0026
Residual 24.03 63 0.3814
CCA DATA NOT COLLECTED
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CCA+ RA: COX-IV 
 
 
 
 
 
 
 
Veh 9cisRA ATRA CCA 9cisRA+CCA ATRA+CCA
N1 0.576586 0.351802 0.360395 0.669937 0.7450621 0.500551
N2 0.670905 0.393802 0.183566 1.187018 1.186149 0.7442985
N3 0.417745 0.390821 0.389675 0.934984 0.9978219 0.7608147
N4 0.385946 0.360393 0.569623 1.016755 1.267866 1.133084
N5 0.894968 0.848413 0.778549 1.54226 1.618556 1.159831
N6 0.432908 1.176445 1.357965 1.682505 1.341669 1.759642
N7 1.187054 0.806337 0.927649 1.708059 1.722744 1.909719
N8 0.506479 0.355647 0.341462 1.178301 1.001869 0.9542009
N9 0.761931 0.76462 0.746358
N10 0.723015 0.8826 0.895053
N11 0.902192 0.726687 0.593574
N12 0.506048 0.708304 0.832317
N13 0.762269 0.751864 0.623995
Two-way ANOVA Ordinary
Alpha 0.05
Source of Variation % of total variationP v lue P value summarySignificant?
Interaction 0.538 0.8125 ns No
cca 1.334 0.3133 ns No
drug 16.88 0.0026 ** Yes
ANOVA table SS DF MS F (DFn, DFd)P value
Interaction 0.1589 2 0.07944 F (2, 63) = 0.2083P = 0.8125
cca 0.394 1 0.394 F (1, 63) = 1.033P = 0.3133
drug 4.984 2 2.492 F (2, 63) = 6.535P = 0.0026
Residual 24.03 63 0.3814
CCA DATA NOT COLLECTED
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CCA+ RA: Tfam Precursor 
 
 
 
Veh 9cisRA ATRA CCA 9cisRA+CCA ATRA+CCA
N1 0.717716 0.28666 0.372199 0.449609 0.450516113 0.482701329
N2 0.637772 0.447698 0.696437 0.624333 0.413127948 0.393573514
N3 0.782092 0.643529 0.766415 0.963671 0.798638492 0.745782072
N4 1.038424 0.879517 0.938006 1.008567 0.843441512 0.980792933
N5 1.019391 0.9191 0.965538 0.863256 0.48551608 1.093691828
N6 1.105406 0.468854 0.688911 0.278635 0.313127618 0.281241919
N7 0.987016 0.387483 0.402116 0.547151 0.487094208 1.079255557
Two-way ANOVA Ordinary
Alpha 0.05
Source of Variation % of total variationP v lue P value summarySignificant?
Interaction 4.292 0.3921 ns No
cca 2.062 0.343 ns No
drug 13.26 0.0641 ns No
ANOVA table SS DF MS F (DFn, DFd)P value
Interaction 0.1216 2 0.0608 F (2, 36) = 0.9610P = 0.3921
cca 0.05843 1 0.05843 F (1, 36) = 0.9235P = 0.3430
drug 0.3756 2 0.1878 F (2, 36) = 2.969P = 0.0641
Residual 2.278 36 0.06327
T-test
Table Analyzed TFAM Precursor Vehicle vs 9cisRA
Column B 9cisRA
vs. vs.
Column A Vehicle
Unpaired t test
P value 0.0164
P value summary *
Significantly different? (P < 0.05)Yes
One- or two-tailed P value?Two-tailed
t, df t=2.788 df=12
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CCA+ RA: Tfam Mature 
 
 
 
Veh 9cisRA ATRA CCA 9cisRA+CCA ATRA+CCA
N1 0.959341 0.46131 0.317739 1.111104 0.465016884 0.461252783
N2 0.709618 0.422844 0.570822 1.291391 0.752827692 0.583137915
N3 0.700575 0.719201 0.92461 0.588309 0.704367661 1.022193403
N4 0.964957 0.884821 1.156858 0.630865 0.635108801 0.602982154
N5 0.491197 0.625081 1.005203 1.526552 0.784529237 1.152074262
N6 1.33516 0.57428 0.640637 0.877593 0.583579659 0.537773232
N7 1.062356 0.539625 0.562929 1.059715 0.701270455 0.849769505
Two-way ANOVA Ordinary
Alpha 0.05
Source of Variation % of total variationP v lue P value summarySignificant?
Interaction 0.7924 0.8268 ns No
cca 1.269 0.4389 ns No
drug 23.36 0.0074 ** Yes
ANOVA table SS DF MS F (DFn, DFd)P value
Interaction 0.02482 2 0.01241 F (2, 36) = 0.1913P = 0.8268
cca 0.03976 1 0.03976 F (1, 36) = 0.6127P = 0.4389
drug 0.7317 2 0.3658 F (2, 36) = 5.637P = 0.0074
Residual 2.336 36 0.0649
T-test
Table Analyzed TFAM Mature veh vs 9cisRA
Column B 9cisRA
vs. vs.
Column A Vehicle
Unpaired t test
P value 0.0365
P value summary *
Significantly different? (P < 0.05)Yes
One- or two-tailed P value?Two-tailed
t, df t=2.354 df=12
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CCA+ RA: Citrate Synthase 
 
 
 
 
 
 
 
 
 
 
 
 
Veh 9cisRA ATRA CCA 9cisRA+CCA ATRA+CCA
N1 1.218517 1.638595 1.24825 0.872496 1.28885969 1.348548924
N2 0.477796 0.418204 0.380803 0.360741 0.407432506 0.700702689
N3 0.438496 0.630846 0.437916 0.434156 0.570479114 0.495943666
N4 0.805329 0.743812 0.674896 0.578441 0.724846529 0.770442202
N5 0.671708 0.682338 0.665853 0.613962 0.706618033 0.852226655
N6 0.775183 0.90004 0.722866 0.741863 0.994289977 1.114188489
Two-way ANOVA Ordinary
Alpha 0.05
Source of Variation % of total variationP v lue P value summarySignificant?
Interaction 5.29 0.4259 ns No
cca 0.00173 0.981 ns No
drug 4.366 0.4926 ns No
ANOVA table SS DF MS F (DFn, DFd)P value
Interaction 0.1704 2 0.08522 F (2, 30) = 0.8784P = 0. 259
cca 5.57E-05 1 5.57E-05 F (1, 30) = 0.0005744P = .9810
drug 0.1407 2 0.07034 F (2, 30) = 0.7250P = 0.4926
Residual 2.911 30 0.09702
79 
 
CCA+ RA: PGC-1 alpha 
 
 
 
 
 
 
 
 
Veh 9cisRA ATRA CCA 9cisRA+CCA ATRA+CCA
N1 0.426403 1.075626 1.092075 0.741982 1.201746 1.304382
N2 0.334808 1.40211 1.339539 0.532943 1.63813 0.9441478
N3 0.654628 0.963233 0.717858 0.909767 0.9594332 1.220115
N4 0.7333 0.922234 0.582435 0.618605 0.9772882 1.350956
N5 0.984332 1.924525 2.582839 1.257874 1.915074 1.951808
N6 1.187963 2.625586 2.649163 1.761471 2.580405 4.110325
N7 0.713296 1.040137 0.921605
N8 0.8991 0.801991 0.696777
N9 0.645766 1.029698 0.773903
N10 0.533626 0.687954 0.790714
N11 1.105614 1.024698 0.839868
N12 0.796258 0.801914 1.142197
N13 0.873989 1.178082 1.072798
Two-way ANOVA Ordinary
Alpha 0.05
Source of Variation % of total variationP v lue P value summarySignificant?
Interaction 1.585 0.596 ns No
cca 7.887 0.0268 * Yes
drug 14.24 0.0134 * Yes
ANOVA table SS DF MS F (DFn, DFd)P value
Interaction 0.4018 2 0.2009 F (2, 51) = 0.5229P = 0.5960
cca 1.999 1 1.999 F (1, 51) = 5.203P = 0.0268
drug 3.61 2 1.805 F (2, 51) = 4.697P = 0.0134
Residual 19.6 51 0.3843
CCA DATA NOT COLLECTED
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CCA+ RA: NRF-1 
 
 
 
 
 
 
 
 
 
 
 
 
 
Veh 9cisRA ATRA CCA 9cisRA+CCA ATRA+CCA
N1 1.744831 1.754957 1.732793 1.674159 1.513267251 1.627157004
N2 1.577869 1.369597 1.518797 1.638734 1.88649025 0.954721074
N3 0.950118 1.081567 1.218517 0.976574 0.717634015 1.153138531
N4 1.063766 0.874403 0.988773 1.210048 0.900682157 1.35375297
Two-way ANOVA Ordinary
Alpha 0.05
Source of Variation % of total variationP v lue P value summarySignificant?
Interaction 0.6543 0.9419 ns No
cca 0.1107 0.8882 ns No
drug 1.262 0.8912 ns No
ANOVA table SS DF MS F (DFn, DFd)P value
Interaction 0.0179 2 0.00895 F (2, 18) = 0.06011P = .9419
cca 0.003029 1 0.003029 F (1, 18) = 0.02034P = .8882
drug 0.03453 2 0.01727 F (2, 18) = 0.1160P = 0.8912
Residual 2.68 18 0.1489
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CCA+ RA: LC3 II/I 
 
 
 
 
Veh 9cisRA ATRA CCA 9cisRA+CCA ATRA+CCA
N1 1.374014 1.354117 1.290407 0.527991 0.4941397 0.8020372
N2 1.224006 1.348731 1.109691 1.158963 0.6078364 0.9118378
N3 0.850524 1.064299 0.987267 0.296409 0.3305946 0.4534357
N4 0.994319 1.03971 1.342847 0.479124 0.6401998 0.5984518
N5 0.559401 0.681252 0.681439
N6 0.96133 0.817394 0.787624
N7 0.652155 0.774135 0.719689
N8 0.732835 0.595804 0.867135
Two-way ANOVA Ordinary
Alpha 0.05
Source of Variation % of total variationP v lue P value summarySignificant?
Interaction 3.416 0.5538 ns No
cca 8.535 0.0929 ns No
drug 4.766 0.4412 ns No
ANOVA table SS DF MS F (DFn, DFd)P value
Interaction 0.03539 2 0.01769 F (2, 30) = 0.6028P = 0.5538
cca 0.08841 1 0.08841 F (1, 30) = 3.012P = 0.0929
drug 0.04937 2 0.02469 F (2, 30) = 0.8409P = .4412
Residual 0.8807 30 0.02936
T-test
Column B 9cisRA+CCA
vs. vs.
Column A Control
Unpaired t test
P value 0.0148
P value summary *
Significantly different? (P < 0.05)Yes
One- or two-tailed P value?Two-tailed
t, df t=2.939 df=10
CCA DATA NOT COLLECTED
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CCA+ RA: p62 
 
 
 
 
 
 
 
 
 
Veh 9cisRA ATRA CCA 9cisRA+CCA ATRA+CCA
N1 0.964251 1.345813 2.08312 1.862169 2.038981 1.993075
N2 1.090918 2.390689 1.760276 1.888766 1.395961 1.436267
N3 1.495361 1.933011 1.787895 1.80353 2.127916 2.647257
N4 2.738294 2.503004 1.835485 2.142894 2.326725 1.470028
N5 1.132009 1.916121 2.057727 1.82004 1.785906 1.953936
N6 1.261405 1.455852 1.334878 1.106211 1.32972 1.081594
N7 1.260569 1.039772 0.641423
N8 0.762524 0.854552 0.907328
N9 1.164486 1.738607 1.63267
N10 2.190985 1.63286 1.72674
Two-way ANOVA Ordinary
Alpha 0.05
Source of Variation % of total variationP v lue P value summarySignificant?
Interaction 0.815 0.8299 ns No
cca 5.232 0.1284 ns No
drug 1.812 0.662 ns No
ANOVA table SS DF MS F (DFn, DFd)P value
Interaction 0.09668 2 0.04834 F (2, 42) = 0.1873P = 0.8299
cca 0.6206 1 0.6206 F (1, 42) = 2.405P = 0.1284
drug 0.215 2 0.1075 F (2, 42) = 0.4165P = 0.6620
Residual 10.84 42 0.258
CCA DATA NOT COLLECTED
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CCA+ RA: Beclin 
 
 
 
 
 
 
 
 
 
 
 
Veh 9cisRA ATRA CCA 9cisRA+CCA ATRA+CCA
N1
N2 1.917064 1.498013 1.938439 1.420024 1.553702934 1.775219518
N3 1.542369 2.599375 2.251252 3.134473 1.767070007 1.723545021
N4 1.858023 1.184313 0.980516 0.835418 1.095158663 0.686373182
N5 0.847596 1.391481 1.222222 1.029621 1.473350071 1.031386015
N6 2.534593 1.891389 1.549435 1.011436 1.108698328 1.773088509
N7 2.271364 1.612242 1.934172 0.916335 1.14066068 0.891810858
Two-way ANOVA Ordinary
Alpha 0.05
Source of Variation % of total variationP v lue P value summarySignificant?
Interaction 0.1867 0.9686 ns No
cca 11.17 0.0599 ns No
drug 0.9466 0.8513 ns No
ANOVA table SS DF MS F (DFn, DFd)P value
Interaction 0.02057 2 0.01028 F (2, 30) = 0.03194P = 0. 686
cca 1.231 1 1.231 F (1, 30) = 3.823P = 0.0599
drug 0.1043 2 0.05213 F (2, 30) = 0.1619P = 0.8513
Residual 9.659 30 0.322
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CCA+ RA: Tim23
 
Veh 9cisRA ATRA CCA 9cisRA+CCA ATRA+CCA
N1 1.243396 2.486152 3.191163 1.709234 2.828723 2.581458
N2 0.873672 1.34927 1.203369 1.166294 1.060119 0.5242305
N3 1.792207 1.749553 1.729326 0.697743 1.384781 1.450562
N4 0.644062 1.040971 1.209887 0.975667 0.9375689 0.8791537
N5 0.900882 1.397515 1.895195 2.241009 2.360801 2.35036
N6 0.651785 1.210369 1.036504
N7 0.691095 0.884985 1.007745
N8 0.925122 1.644361 2.805973
N9 0.602558 0.822988 0.851506
N10 0.568686 0.939952 0.906231
N11 0.890214 1.015765 0.991923
Two-way ANOVA Ordinary
Alpha 0.05
Source of Variation % of total variationP v lue P value summarySignificant?
Interaction 1.801 0.6377 ns No
cca 4.257 0.1501 ns No
drug 7.176 0.1759 ns No
ANOVA table SS DF MS F (DFn, DFd)P value
Interaction 0.3826 2 0.1913 F (2, 42) = 0.4548P = 0.6377
cca 0.904 1 0.904 F (1, 42) = 2.149P = 0.1501
drug 1.524 2 0.762 F (2, 42) = 1.812P = 0.1759
Residual 17.67 42 0.4206
T-test
Table Analyzed Tim23 Veh to ATRA
Column B ATRA
vs. vs.
Column A Vehicle
Unpaired t test
P value 0.0252
P value summary *
Significantly different? (P < 0.05)Yes
CCA DATA NOT COLLECTED
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CCA+ RA: Tom40 
 
 
 
 
 
 
 
 
Veh 9cisRA ATRA CCA 9cisRA+CCA ATRA+CCA
N1 0.796204 1.867084 1.880158 1.009332 2.410642046 1.852778211
N2 0.142918 0.235456 0.478468 0.443115 0.81299217 0.739861155
N3 0.352892 0.7917 0.851708 0.894238 1.209869308 0.808411142
N4 0.880494 1.274893 1.479337 1.021877 1.125361063 1.271153715
N5 0.497801 0.808087 1.538402 1.338921 0.855726456 1.274848252
N6 0.607419 0.687 0.892972 0.720008 0.836872346 1.129833968
N7 0.57637 0.661053 1.328154
N8 0.792832 0.907605 0.89625
N9 0.868492 1.290346 1.282801
N10 0.313478 0.667871 0.671202
N11 0.543811 0.727438 0.52254
N12 0.760941 0.793788 1.092412
N13 0.664544 1.322355 0.777182
Two-way ANOVA Ordinary
Alpha 0.05
Source of Variation % of total variationP v lue P value summarySignificant?
Interaction 0.7458 0.7807 ns No
cca 6.687 0.0396 * Yes
drug 12.29 0.0223 * Yes
ANOVA table SS DF MS F (DFn, DFd)P value
Interaction 0.07776 2 0.03888 F (2, 51) = 0.2488P = 0.7807
cca 0.6973 1 0.6973 F (1, 51) = 4.461P = 0.0396
drug 1.282 2 0.6409 F (2, 51) = 4.101P = 0.0223
Residual 7.971 51 0.1563
CCA DATA NOT COLLECTED
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CCA+ RA: mtHsp60 
 
 
 
 
 
 
 
 
 
 
 
 
 
Veh 9cisRA ATRA CCA 9cisRA+CCA ATRA+CCA
N1 1.425384 1.574645 1.723214 1.530523 1.239547495 1.629245833
N2 0.673344 0.757804 0.685609 0.62859 0.647041334 0.613678254
N3 0.501352 0.524985 0.421478 0.434953 0.544432541 0.328989707
N4 1.218604 1.665865 1.269404 2.028819 1.684826149 2.11764157
Two-way ANOVA Ordinary
Alpha 0.05
Source of Variation % of total variationP v lue P value summarySignificant?
Interaction 1.408 0.8795 ns No
cca 0.5462 0.755 ns No
drug 0.1024 0.9906 ns No
ANOVA table SS DF MS F (DFn, DFd)P value
Interaction 0.1045 2 0.05226 F (2, 18) = 0.1293P = 0.8795
cca 0.04056 1 0.04056 F (1, 18) = 0.1004P = .7550
drug 0.007603 2 0.003801 F (2, 18) = 0.009408P = 0.9906
Residual 7.273 18 0.4041
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CCA+ RA: mtHsp70 
 
 
 
 
 
 
 
 
Veh 9cisRA ATRA CCA 9cisRA+CCA ATRA+CCA
N1 1.805861 1.495881 1.43061 1.539157 1.600956923 1.543890545
N2 0.615733 0.669282 0.672455 0.445395 0.560272143 0.316462208
N3 0.573586 0.178991 0.435642 0.517167 0.261483583 0.361693936
N4 3.148214 3.153754 2.497906 2.872071 3.069393655 3.075177099
N5 2.09942 2.613112 2.630495 2.401572 3.222521524 3.600406041
N6 1.194223 1.447779 1.419924 1.783551 1.794438417 1.450527448
N7 1.13107 1.216373 0.968662
N8 0.819392 1.156899 0.953944
N9 0.939154 1.451114 2.68602
N10 0.830507 0.853733 0.859824
N11 0.802285 1.027037 1.1338
N12 0.952386 1.065727 0.974268
N13 0.933032 1.006466 0.985177
Two-way ANOVA Ordinary
Alpha 0.05
Source of Variation % of total variationP v lue P value summarySignificant?
Interaction 0.01403 0.9963 ns No
cca 4.151 0.1423 ns No
drug 0.4559 0.8854 ns No
ANOVA table SS DF MS F (DFn, DFd)P value
Interaction 0.006218 2 0.003109 F (2, 51) = 0.003754P = 0.9963
cca 1.839 1 1.839 F (1, 51) = 2.221P = 0.1423
drug 0.202 2 0.101 F (2, 51) = 0.1220P = 0.8854
Residual 42.24 51 0.8283
CCA DATA NOT COLLECTED
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RA: Kinase Activity: phosphorylated/total ratio of AMPK 
 
 
 
 
 
 
 
 
 
 
 
 
 
Veh 9cisRA ATRA
N1 0.176462509 0.472397669 0.365738989
N2 0.421778008 0.310882277 0.675900491
N3 0.384068166 0.708759018 0.643799205
N4 0.750008445 0.896652621 1.077093233
N5 1.596853176 1.324893361 1.210249766
N6 1.348778124 1.274451892 0.901556004
Table Analyzed p/t AMPK 30min
ANOVA summary
F 0.02063
P value 0.9796
P value summary ns
ANOVA table SS DF MS F (DFn, DFd)P value
Treatment (between columns) 0.008203 2 0.004101 F (2, 15) = 0.02063P = .9796
Residual (within columns) 2.983 15 0.1989
Total 2.991 17
89 
 
RA: Kinase Activity: phosphorylated/total ratio of p38/MAPK 
 
 
 
 
 
 
 
 
 
 
 
 
 
Veh 9cisRA ATRA
N1 0.922871396 0.72288687 0.920516551
N2 1.213092944 0.712817239 0.636755186
N3 0.620556995 0.584798374 1.126938926
N4 0.726986314 0.64897811 1.181976903
N5 0.769110677 0.562716186 0.292087081
N6 1.165390636 1.169154636 0.448560188
Table Analyzed p/t-p38 30 min
ANOVA summary
F 0.596
P value 0.5635
P value summary ns
ANOVA table SS DF MS F (DFn, DFd)
Treatment (between columns)0.09632 2 0.04816 F (2, 15) = 0.5960
Residual (within columns) 1.212 15 0.08081
Total 1.308 17
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RA: Kinase Activity: phosphorylated/total ratio of CAMK II 
 
 
 
 
 
 
 
 
 
 
 
 
 
Veh 9cisRA ATRA
N1 0.922871396 0.72288687 0.920516551
N2 1.213092944 0.712817239 0.636755186
N3 0.620556995 0.584798374 1.126938926
N4 0.726986314 0.64897811 1.181976903
Table Analyzed p/t-CAMK 30 min
ANOVA summary
F 2.109
P value 0.1774
P value summary ns
ANOVA table SS DF MS
Treatment (between columns)0.1868 2 0.09338
Residual (within columns) 0.3985 9 0.04428 F (DFn, DFd)
Total 0.5853 11 F (2, 9) = 2.109
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Figure S1. RA isomer-supplemented differentiation leads to elevations in mitochondrial, but not 
nuclear encoded mitochondrial proteins. Myoblast differentiation was supplemented with: 
control (DM), DMSO (Vehicle) and the RA isomers over the course of 4 days with 1µM of RA. 
(A). Representative Western Blots and graphical quantifications of: (B) COX-I, (C) COX-IV. 
Data are registered as mean ±SEM and are measured in arbitrary units. (¶, main effect of RA, 
P<0.05 vs vehicle; n=4).  
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Figure S2. Respiration in RA isomer-treated myotubes. Myotubes were treated with 1µM of RA 
isomers 9cisRA and ATRA . (A). Stage 3 respiration with RA isomer treatment (B) Stage 4 
Respiration with RA isomer treatment.  
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APPENDIX C- LABORATORY METHODS AND PROTOCOLS 
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CELL CULTURE 
Cells 
1. C2C12 murine skeletal muscle cells (ATCC, CRL-1772) 
Materials 
1. Dulbecco’s Modified Eagle’s Medium (DMEM; Sigma D-5796/500ml) 
2. Fetal Bovine Serum (FBS; Fisher Scientifitc SH3039603C/500ml) 
a. Aliquoted into 50ml sterile conical tubes and stored at -20°C 
3. Penicillin/Streptomycin (P/S; Invitrogen 15140-122/100ml) 
a. Sterile aliquots of 6mls and stored at -20°C) 
4. Horse Serum (HS; Invitrogen 16050-114/1000ml) 
a. Aliquoted into 50ml sterile conical tubes and stored at -20°C 
b. Heat-inactivated for 30 minutes at 56.0°C 
5.  0.25% Trypsin-EDTA (1x), phenol red (Invitrogen 25200-072/500ml) 
a. Sterile aliquots of 30mls stored at -20°C 
6. Dulbecco’s Phosphate Buffered Saline (PBS; Sigma D-8537/500ml) 
7. 15ml conical tubes, sterile (BD Falcon 352097) 
8. 50ml conical tubes, sterile (BD Falcon 352098) 
9. 175cm2 canted/vented tissue cultured flasks (BD Falcon 353112) 
10. 6-well sterile tissue culture dish (Sarstedt 83.1839.300) 
11. Gelatin (Sigma G1890) 
a. 0.1% solution autoclaved for sterilization 
 
Procedure 
1. Allow myoblasts to proliferate in 175cm2 flask with growth medium (GM; DMEM supplemented 
with 10% FBS and 1% P/S) until 70% confluent. 
2. Prepare six 6-well dishes for plating by coating the bottom surface with 0.1% gelatin and allow to 
fully dry in laminar flow hood.  
3. Pre-heat GM, trypsin and PBS in 37°C water bath for 30 minutes prior to use. 
4. Discard old GM from tissue culture flask and wash with 10mls of PBS to rinse off remaining 
GM.  
5. Apply 5mls of trypsin in the flask and place in the incubator at 37°C for 3 minutes. 
6. Remove flask from incubator and gently knock sides of the flask to ensure cells are lifted from 
flask bottom. Remove trypsin with cells and place into a sterile 15ml conical tube.  
7. Rinse flask with 5mls GM and add to sterile 15ml conical tube containing the cells. 
8. Spin tube for 3 minutes at 1400rpm at room temperature. 
9. Discard the supernatant and add 1ml of GM for resuspension with 1ml pipette.  
10. Add 3mls of GM to resuspended cell mixture for a total volume of 4mls.  
11. Fill each well of tissue culture dishes with 2mls of GM and add 100µl of cell mixture to each 
well.  
12. Rotate plate in a circular motion for 30secs and subsequently place into 37°C incubator overnight. 
13. The following day remove GM from cells and replace with differentiation medium (DM; DMEM 
supplemented with 5% heat-inactivated HS and 1% P/S) once myoblasts are 90-95% confluent. 
14. Refresh DM every other day. Mature myotubes will form after five days and be ready for 
contractile activity.  
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TREATMENT OF C2C12 MYOTUBES WITH RETINOIC ACID 
Cells 
2. C2C12 murine skeletal muscle cells (ATCC, CRL-1772) 
Materials 
1. Dulbecco’s Modified Eagle’s Medium (DMEM; Sigma D-5796/500ml) 
2. Fetal Bovine Serum (FBS; Fisher Scientifitc SH3039603C/500ml) 
a. Aliquoted into 50ml sterile conical tubes and stored at -20°C 
3. Penicillin/Streptomycin (P/S; Invitrogen 15140-122/100ml) 
a. Sterile aliquots of 6mls and stored at -20°C) 
4. Horse Serum (HS; Invitrogen 16050-114/1000ml) 
a. Aliquoted into 50ml sterile conical tubes and stored at -20°C 
b. Heat-inactivated for 30 minutes at 56.0°C 
5.  0.25% Trypsin-EDTA (1x), phenol red (Invitrogen 25200-072/500ml) 
a. Sterile aliquots of 30mls stored at -20°C 
6. Dulbecco’s Phosphate Buffered Saline (PBS; Sigma D-8537/500ml) 
7. 15ml conical tubes, sterile (BD Falcon 352097) 
8. Dimethyl Sulfoxide (DMSO, Sigma D-8418/100ml) 
9. 50ml conical tubes, sterile (BD Falcon 352098) 
10. 6-well sterile tissue culture dish (Sarstedt 83.1839.300) 
11. All-trans Retinoic Acid,CAS (Cayman Chem, № 302-79-4)(2mM stock) 
12. 9-cis Retinoic acid (Sigma-Aldrich, R4643-1MG) (2mM stock) 
13. 6x 6-well dishes containing differentiated myotubes (Day 4) 
*note that CCA labelled plates require ~4mL of media in order to contact electrode lids 
Procedure 
1. Warm DM (contains DMEM, 5% heat inactivated horse serum, 1% 
Penicillin/Streptomycin) in 37
o
C water bath.  
2. Label  3x15ml, and 3x50mL  tubes, and their corresponding 6 well dishes as Vehicle 
(DMSO) /9cisRA/ATRA, and CCA/9cisRA+CCA/ATRA+CCA 
3. Pipette 11.974mL of DM into 3x15ml tubes, and double the amount in the 50mL tube. 
Add 6µl of 2mM 9cisRA/ATRA, and the equivalent volume of vehicle to the appropriate  
tubes and vortex.  
4. Aspirate old DM present in the 6-6 well plates, wash with PBS, and aspirate PBS.  
5. Aliquot the DM containing vehicle/9cisRA/ATRA into the appropriate 6-well dishes 
6. Store dishes into the incubator for 24h (21 if done in combination with CCA)  
7. Repeat 1-6 over a total of 4 days 
8. Collect and analyze cells.  
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TREATMENT OF C2C12 MYOTUBES WITH NICOTINAMIDE RIBOSIDE 
Cells 
3. C2C12 murine skeletal muscle cells (ATCC, CRL-1772) 
Materials 
1. Dulbecco’s Modified Eagle’s Medium (DMEM; Sigma D-5796/500ml) 
2. Fetal Bovine Serum (FBS; Fisher Scientifitc SH3039603C/500ml) 
a. Aliquoted into 50ml sterile conical tubes and stored at -20°C 
3. Penicillin/Streptomycin (P/S; Invitrogen 15140-122/100ml) 
a. Sterile aliquots of 6mls and stored at -20°C) 
4. Horse Serum (HS; Invitrogen 16050-114/1000ml) 
a. Aliquoted into 50ml sterile conical tubes and stored at -20°C 
b. Heat-inactivated for 30 minutes at 56.0°C 
5.  0.25% Trypsin-EDTA (1x), phenol red (Invitrogen 25200-072/500ml) 
a. Sterile aliquots of 30mls stored at -20°C 
6. Dulbecco’s Phosphate Buffered Saline (PBS; Sigma D-8537/500ml) 
7. 15ml conical tubes, sterile (BD Falcon 352097) 
8. 50ml conical tubes, sterile (BD Falcon 352098) 
9. 6-well sterile tissue culture dish (Sarstedt 83.1839.300) 
10. Nicotinamide Riboside Chloride (CAS#: 23111-00-4) |(100mM stock) 
11. 6 6-well dishes containing differentiated myotubes (Day 4) 
*note that CCA labelled plates require ~4mL of media in order to contact electrode lids 
 
Procedure 
1. Warm DM (contains DMEM, 5% heat inactivated horse serum, 1% 
Penicillin/Streptomycin) in 37
o
C water bath.  
2. Pipette 11.800mL of DM into a 15ml conical tube. Add 200µl of 100mM NR to form a 
final concetration of 1 mM.  
3. Aspirate old DM present in the 6-6 well plates, wash with PBS, and aspirate PBS.  
4. Aliquot the DM containing NR into the appropriate 6-well dishes 
5. Store dishes into the incubator for 24h  
6. Repeat 1-6 over a total of 4 days 
7. Collect and analyze cells 
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PREPARATION OF PROTEIN EXTRACTS FROM CELL CULTURE 
 
Reagents 
 
1. 5X Passive Lysis Buffer diluted in ddH20 to 1X (Promega E194A) 
2. Phosphate Buffered Saline (PBS; Sigma D-8537) 
3. Protease Inhibtors 
a. Leupeptin (10mg/ml stock) 
b. Aprotinin (10mg/ml stock) 
c. Pepstatin (10mg/ml stock) 
d. PMSF (500mM stock) 
e. DTT (1M stock) 
4. Phosphatase Inhibitors 
a. Sodium Orthovanadate (250mM stock) 
b. PhosSTOP tablets (10X concentrated stock) 
 
Procedure 
 
1. Prepare fresh lysis buffer with protease and phosphatase inhibitors. 
2. Remove media and wash cells 3X with 2mls of ice-cold PBS. Aspirate last wash. 
3. Add 150µl of freshly prepared lysis buffer containing protease and phosphatase inhibitors 
into wells. Scrape the wells with a rubber cell scraper and place cell lysate into an 
eppendorf. Place eppendorf on ice. If required, combine multiple wells with a total of 
150µl to increase final protein concentration. 
4. Vortex sample briefly and place in liquid nitrogen. Thaw sample in water bath set to 
37°C for 2 minutes. Repeat step four 2X for a total of 3 freeze-thaw cycles.  
5. Spin the samples at 4°C for 5 minutes at 16.1rcf.  
6. Collect the supernatant and place into a newly labeled eppendorf tube.  
7. Measure the total protein concentration using the Bradford Assay.  
8. Store samples at -20°C. 
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MITOCHONDRIAL ISOLATION FROM C2C12 MYOTUBES 
 
Adapated from: Frezza C, Cipolat S, Scorrano L. Nature Protocols 2007;2(2):287-95. 
 
Materials 
 
1. Cold PBS (Sigma D-8537) 
2. Cell Scraper 
3. Mitochondrial Isolation tubes 
4. Teflon Pestle 
5. Glass Potter 
 
Mitchondrial Isolation Buffer (MIB) 
 
1. 10ml of 0.1M Tris-MOPS 
a. Dissolve 6.05g of Tris in 250ml of ddH20 pH to 7.4 using MOPS powder. 
b. Volume up to 500ml. 
c. Store at 4ºC. 
2. 1ml of 0.1M EGTA/Tris 
a. Dissolve 19.05g of EGTA in 250ml of ddH20 pH to 7.4 using Tris powder/HCl. 
b. Volume up to 500ml. 
c. Store at 4ºC. 
3. 20ml of 1M sucrose 
a. Dissolve 171.65g of sucrose in 500ml of ddH20. Stir until fully dissolved. 
b. Aliquot into 20ml volumes in sterile conical tubes.  
c. Store at -20ºC. 
4. Volume up to 100ml with ddH20.  
5. pH to 7.4. 
6. Store at 4ºC. 
 
Method 
 
1. Pre-heat GM, trypsin in 37°C water bath for 30 minutes prior to use. 
2. Discard old DM from tissue culture flask and wash with 10mls of PBS to rinse off 
remaining GM.  
3. Apply 5mls of trypsin in the flask and place in the incubator at 37°C for 3 minutes. 
4. Remove flask from incubator and gently knock sides of the flask to ensure cells are lifted 
from flask bottom. Remove trypsin with cells and place into a sterile 15ml conical tube.  
5. Rinse flask with 5mls GM and add to sterile 15ml conical tube containing the cells. 
6. Spin tube for 3 minutes at 1400rpm at room temperature. 
7. Discard the supernatant and add 10mL of PBS for resuspension. 
8. Spin tube for 3 mins at 1400rpm at room temperature 
9. Wash cells with cold PBS and resuspend.  
10. Centrifuge the cells at 600g for 10 minutes at 4ºC. 
11. Pre-cool Teflon pestle and glass potter on ice.  
12. Discard the supernate and resuspend the cells in 3mls of ice-cold MIB.  
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13. Transfer cell solution to glass potter.  
14. Homogenize the cells using Teflon pestle at 1600rpm for 30 strokes in the glass potter. 
DO NOT USE A GLASS PESTLE, IT WILL DESTROY THE MITOCHONDRIA! 
15. Transfer the homogenate from the glass potter to mitochondrial isolation tube. 
16. Centrifuge at 600g for 10 minutes at 4ºC. 
17. Collect the supernate (contains mitochondria and cytosol) and place into a second clean 
pre-chilled mitochondrial isolation tube.  
18. Centrifuge the supernate at 7000g for 10 minutes at 4ºC. 
19. Discard the supernate and the resultant pellet is the mitochondria. 
20. Gently wash and resuspend the pellet with 200µl of MIB. 
21. Transfer mitochondrial solution to a 1.5ml eppendorf. 
22. Spin in a microcentrifuge at 7000g for 10 minutes at 4ºC. 
23. Discard the supernate and resuspend the mitochondrial pellet with 50-100µl of MIB 
depending on mitochondrial yield.  
24. Use fresh mitochondria immediately for respiration analysis.  
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RESPIRATION OF ISOLATED MITOCHONDRIA FROM CELLS 
 
Materials 
1. Hamilton syringe 
2. Oxygen electrode 
 
Reagents 
 
1. VO2 buffer  
a. Combine the following in a clean beaker 
i. 250mM sucrose 5.13g 
ii. 50mM KCl  0.222g 
iii. 25mM Tris base 0.18g 
iv. 10mM K2HPO4 0.104g 
b. Add 30mls of ddH20 to the beaker and stir until everything is dissolved. 
c. pH to 7.4 
d. Volume up to 60µl in a graduated cylinder. 
e. Place solution into clean bottle, label and store at 4ºC. 
f. Solution is good for one week only. 
2. Glutamate  
a. Make 2X concentrated solution of 123.34mg/ml in ddH20 
3. ADP 
a. Make a 2X concentrated solution of 11.27mg.ml in ddH20 
4. NADH 
a. Make a 2X concentrated solution of 119.18mg.ml in ddH20 
 
Method 
 
1. Turn on water bath to 30ºC to warm the electrode unit. Ensure electrode is clean of all 
debris and membrane is intact. Rinse with ddH20 if necessary. 
2. Turn on oxygen meter and open 782 oxygen system software on the connected computer.  
3. Make glutamate, ADP and NADH solutions fresh in eppendorfs. Place on ice.  
4. Once electrode has reached 30ºC add 250µl of VO2 buffer and 50µl of mitochondria. 
(Minimum volume for the oxygen chamber is 300µl) 
5. Place miniature stir bar in oxygen chamber and stir to mix VO2 buffer and mitochondria. 
Place cork on top of chamber and ensure no air is in the chamber with the mitochondria 
and VO2 buffer.   
6. Let the solution stabilize and then using the software program calibrate the solution in the 
oxygen chamber to “high”. 
7. After calibration is complete let the software record the basal drift for 2 minutes.  
8. Warm glutamate in the 30ºC water bath. 
9. Add 5µl of glutamate (State IV) using the Hamilton syringe and record changes in 
oxygen consumption for at least 2 minutes. 
10. Warm ADP in the 30ºC water bath. 
11. Add 5µl of ADP (State III) with the Hamilton syringe and record changes in oxygen 
consumption for at least 2 minutes.  
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12. Add 5µl of NADH with the Hamilton syringe and record any changes in oxygen 
consumption. This is to test for any damaged mitochondria as NADH would need a 
cellular transporter to get inside intact mitochondria. 
13. Determine protein concentration of isolated mitochondria immediately using the 
Bradford assay.  
14. Analyze rates of oxygen consumption using the software provided. Values are in %O2/ 
hour needs to be converted to %O2/min.  
15. Correct oxygen consumption for protein concentration.  
 
 
Equation:  
 
natoms O2/mg/min =          %O2/min          X     (1000 x 111.25) 
    total µg of protein               100 
 
%O2/min – oxygen consumption (State IV or III) corrected for basal drift 
Total µg of protein – volume of mitochondria x µg/µl of mitochondria 
1000 – to convert from µg to mg 
111.25 – amount of O2 in 250µl of VO2 buffer (0.25mls buffer = 111.25 natoms O2) 
100 – to get percentage 
 
Example Calculation: 
 
Basal drift = 20.00/hr 
State III %O2/hr = 160.00/hr  
Volume of VO2 buffer = 250µl 
Volume of mitochondria = 50µl 
Protein concentration of mitochondria = 4µg/µl 
 
State III %O2/min = (160-20)/60 = 2.3 
Total µg of protein = 50µl x 4µg/µl = 200µg 
 
 
       2.3   X     (1000 x 111.25)     = 12.79natoms O2/mg/min 
      200        100 
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WESTERN BLOTTING AND IMMUNODETECTION 
 
Reagents 
 
1. Transfer Buffer 
a. 0.025M Tris-HCl pH 8.3  12.14g 
b. 0.15M Glycine   45.05g 
c. 20% Methanol  800ml 
d. make up to 4L with ddH20 
e. store at 4°C 
2. Ponceau S stain 
a. 0.1% (w/v) Ponceau S  
b. 0.5% (v/v) Acetic Acid 
c. Store at room temperature 
3. Wash Buffer 
a. Tris-HCl pH 7.5  12g 
b. NaCl   58.5g 
c. 0.1% Tween  10ml 
d. Store at room temperature 
4. Blocking Solution 
a. 5% (w/v) skim milk power in wash buffer OR 
b. 5% (w/v) BSA in wash buffer 
5. Enhanced Chemiluminescence Fluid (ECL; Santa Cruz sc-2048) 
6. Film/Developer/Fixer 
 
Procedure 
 
1. Transfer Procedure 
a. Remove electrophoresis plates from chamber and separate the plates. 
b. Cut away unnecessary parts of the gel using a spatula and measure remaining gel 
size. 
c. Using a paper cutter cut 6 pieces of Whatman paper per gel to the same size as the 
gel. Wearing gloves cut nitrocellulose membrane (GE Healthcare RPN303D) to 
the dimensions of the gel.  
d. Assemble Whatman paper, nitrocellulose memebrane and gel as shown below: 
 
e. Close the cassette and place in the transfer chamber with the black side of the 
cassette facing the back side of the chamber.  
f. Place ice pack in the chamber. 
g. Place lid on the chamber and connect the leads to the power supply.  
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h. Turn on the power supply and run at 120V for 2 hours. This can vary depending 
on the size of the protein of interest. 
2. Removal of transfer membrane: 
a. Turn off the power supply and disconnect leads from the power supply then 
remove the lid from the chamber. 
b. Remove the cassette from the chamber.  
c. With gloves on, remove the Whatman paper and gel and place the nitrocellulose 
membrane in a plastic dish.  
d. Add Ponceau S stain on the membrane and gently swirl.  
e. Drain off the remaining Ponceau S and save for reuse. 
f. Rinse the membrane with ddH20 to reduce the red background. Wrap membrane 
in saran wrap and scan image. 
g. Cut the membrane while protein bands are still visible at the desired molecular 
weight. 
h. Rotate membrane at room temperature in wash buffer until remaining Ponceau S 
has been removed. 
i. Incubate membrane for 1 hour with rotation in blocking solution.  
j. Incubate membrane with desired antibody diluted in blocking solution overnight 
at 4ºC. Membrane is placed face down into the solution on a glass plate covered 
in parafilm. To maintain a moist environment overnight, wet a small kimwipe and 
form it into a ball and place in each corner of the dish. Cover the dish with saran 
wrap. 
3. Immunodetection 
a. Wash the blots in wash buffer with gentle rotation for 5 minutes 3X. 
b. Incubate the blots for 1-2 hours with the appropriate secondary antibody diluted in 
blocking solution. 
c. Membrane is placed face down in solution on a glass plate covered with parafilm. 
Place moist kimwipes in each corner of the dish and cover the dish with saran 
wrap. 
d. Following the incubation, wash the membrane 3X for 5 minutes with wash buffer. 
4. Enhanced Chemiluminescence Detection 
a. Mix ECl fluids “A” and “B” in a 1:1 ratio in a disposable Rohr tube. 
b. Place blots on saran wrap face up and apply ECL solution for 2 minutes.  
c. Dab off excess ECL on a kimwipe and place blots face down on a fresh piece of 
saran wrap and wrap tightly. 
d. Expose blot to film (time will vary depending on protein and antibody).  
e. Place film into developer (time will vary). 
f. Once image appears place film into fixer for 2 minutes. Wash with fresh water 
when complete. 
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SDS POLYACRYLAMIDE GEL ELECTROPHORESIS (SDS-PAGE) 
PROTEAN BIO-RAD SYSTEM 
 
Reagents 
 
1. Acrylamide/Bis-Acrylamide, 30% Solution 37.5:1 (BioShop 10.502) 
a. Store at 4°C 
2. Under Tris Buffer 
a. 1M Tris-HCl, pH 8.8 (60.5g/500ml) 
b. Store at 4°C 
3. Over Tris Buffer 
a. 1M Tris-HCl, pH 6.8 (12.1g/100ml) 
b. Bromophenol Blue (for colour) 
c. Store at 4°C 
4. Ammonium Persulfate (APS) 
a. 10% (w/v) APS in ddH20 (1g/10ml) 
b. Stored at 4°C 
5. Sodium Dodecyl Sulfate (SDS) 
a. 10% (w/v) in ddH20 (1g/10ml) 
b. Store at room temperature 
6. TEMED (Sigma T-9281) 
7. Electrophoresis Buffer, pH 8.3 (10L) 
a. 25mM Tris 30.34g, 192mM Glycine 144g, 0.1% SDS 10g 
b. Volume to 10L with ddH20 
c. Store at room temperature 
8. 6X SDS 
a. Warm 100% glycerol in water bath at 65°C for 30 minutes 
b. Combine 1.2g SDS, 0.06g Bromophenol Blue, 3mls of 1M Tris, pH 6.8 and 1ml 
of ddH20 and stir at 4°C for 5 minutes 
c. Add 3mls of 100% glycerol, stir and aliquot mixture. 
d. Store at -20°C 
e. Add 5% (v/v) ß-mercaptoethanol (Sigma M6250) to 6X SDS just prior to use 
9. tert-Amyl alcohol ReagentPLus, 99% (Sigma 152463) 
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Procedure 
 
1. Prepare electrophoresis rack: 
a. Clean glass plates thoroughly with soap followed by 95% ethanol then ddH20.  
b. Dry carefully with a kimwipe.  
c. Assemble glass plates as shown below: 
 
 
d. Check the seal y adding a small volume of ddH20 then pour off and let dry.  
2. Prepare separating gels: 
a. Mini Protean 3 Bio-Rad System volumes: 
 
 8% 10% 12% 15% 18% 
Acrylamide 2.7 ml 3.3 ml 4.0 ml 5.0 ml 6.0 ml 
ddH20 4.1 ml 3.5 ml 2.8 ml 1.8 ml 0.8 ml 
Under Tris 3.0 ml 3.0 ml 3.0 ml 3.0 ml 3.0 ml 
SDS 100µl 100µl 100µl 100µl 100µl 
APS 100µl 100µl 100µl 100µl 100µl 
TEMED 10µl 10µl 10µl 10µl 10µl 
 
b. Mix the contents of the separating gel without adding APS or TEMED. Stir.  
c. Add APS and TEMED. Stir.  
d. Slowly pour the entire volume of the solution into the space between the two 
plates while keeping plates tilted to prevent bubble formation. 
e.  Add tert-Amyl alcohol to coat top surface of gel solution. 
f. Allow 30 minutes for gel polymerization.  
g. Remove tert-Amyl alcohol by pouring it off and remove any remainder with a 
kimwipe. Rinse with ddH20. 
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3. Prepare stacking gel: 
a. For a single mini gel use the following volumes: 
 
Acrylamide 500 µl 
Over Tris 625 µl 
ddH20 3.75 ml 
SDS 50 µl 
APS 50 µl 
TEMED 7.5 µl 
 
b. Mix the contents of the stacking gel without adding APS or TEMED. Stir.  
c. Add APS and TEMED. Stir.  
d. Using a Pasteur pipette slowly add the entire volume from the beaker in between 
the plates.  
e. Add comb for desired number of wells. 
f. Allow 30 minutes for gel polymerization. 
 
4. Prepare samples: 
a. Turn of the block heater to 95ºC.  
b. Pipette required volume of sample into new eppendorf with 6X SDS (1 volume of 
sample to 1/6 sample volume of 6X SDS). Keep samples on ice until all samples 
are prepared. 
c. Briefly spin each sample to bring volume to the bottom of the eppendorf. 
d. Incubate each sample at 95 ºC for 5 minutes in the heating block to denature the 
proteins.  
e. Briefly spin again to return volume to the bottom of the eppendorf. 
 
5. Assemble Mini-PROTEAN gel caster system: 
a. See images below: 
 
 
b. If you are only running one gel a plastic rectangular pseudo plate must be 
clamped on the other side of the caster.  
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c. Fill with electrophoresis buffer between the plates and outside of the plates in the 
chamber.  
d. Slowly remove the comb using both hands (one on each side) by pulling the comb 
straight upwards.  
e. Fix any wells that are deformed using a small spatula.  
f. Clean out the wells using a syringe filled with electrophoresis buffer.  
g. Withdraw the entire volume of the sample using a Hamilton syringe. Inject 
volume slowly into the bottom of the well.  
 
6. Gel electrophoresis  
a. Immediately after all samples are loaded place the lid on the gel chamber. 
b. Place positive and negative plugs into the power supply and turn on power supply.  
c. Set power supply to 120V. Gel will run for ~2 hours depending on percent gel 
made. 
d. When the bromophenol blue has run off the bottom of the gel turn off the power 
supply. Remove plugs from power supply and remove lid. 
e. Prepare for electrotransfer of proteins from the gel to nitrocellulose membrane.  
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ELECTRICAL STIMULATION OF MYOTUBES IN CULTURE 
 
Cells 
 
1. C2C12 murine skeletal muscle cells, differentiated into mature myotubes 
 
Materials 
 
1. Electrical Stimulator 
Gange bipolar output (+/- amplitude adjustable using one knob) 
Output voltage range = 0 to +/- 30V 
Maximum output current = 1A 
Adjustable output pulse duration from 0.001 to 0.1secs (10-1kHz) 
Adjustable output pulse repetition from 0.0005 to 0.01secs (100-2kHz) 
Adjustable polarity duration range from 1 to 100secs (0.01 to 1Hz) 
Polarity duration range = time duration for the output “pulse burst” to be positive before 
switching to a similar negative (amplitude) pulse burst. Positive and negative duration are 
of equal value except for the amplitude.  
 
2. 6-well sterile plastic culture dishes (Sarstedt 83.1839.300) with lids modified for    
implantation of platinum electrode wires (see image below). Bottom of plates should be 
coated with sterile 0.1% gelatin.  
 
Procedure 
 
1. Before each bout of stimulation, electrodes are cleaned with 70% ethanol and placed in 
the laminar flow hood for 30mins under UV light for sterilization.  
2. DM is refreshed 30mins prior to stimulation protocol. 
3. Differentiated myotubes are stimulated in a parallel circuit (four 6-well dishes at once) at 
5Hz, 9V for 3 hours in 2mls of DM.  
4. Once the 3 hours is complete, DM should be refreshed once again.  
5. The cells are allowed to rest for 21 hours until the next bout of stimulation. The total 
protocol lasts for 4 days and 21 hours and cells are harvested following the last 21 hour 
rest period.  
 
A) Electrical Stimulator    B) Modified six-well plate lid 
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, 2018.  
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